PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34307188-2 2021 In this context, single nucleotide polymorphisms (SNPs) in the locus of interferon lambda 3 and 4 genes (IFNL3/4) have been important genetic markers of responsiveness to CHC as prognostic markers for the pegylated-Interferon-alpha/ribavirin (Peg-IFN-alpha/RBV). Ribavirin 232-241 interferon alpha 1 Homo sapiens 247-256 32024338-10 2020 Conclusion: This study revealed an association between subclinical thyroid dysfunction and treatment with IFN-alpha and Ribavirin in children. Ribavirin 120-129 interferon alpha 1 Homo sapiens 106-115 32885325-2 2020 The aim of this study was to investigate the effect of pegylated interferon alpha (IFNalpha) + ribavirin (PegIFNalpha+RVB) or sofosbuvir + NS5A inhibitor (SOF+InNS5A) on IR and the components of OS. Ribavirin 95-104 interferon alpha 1 Homo sapiens 106-117 32346535-6 2020 Interferon-alpha (IFN-alpha) and its analogs, pegylated IFN-alpha (PEG-IFN-alpha) alone with ribavirin (RBV), have been the primary antiviral treatment of HCV for many years with a low cure rate. Ribavirin 93-102 interferon alpha 1 Homo sapiens 18-27 32346535-6 2020 Interferon-alpha (IFN-alpha) and its analogs, pegylated IFN-alpha (PEG-IFN-alpha) alone with ribavirin (RBV), have been the primary antiviral treatment of HCV for many years with a low cure rate. Ribavirin 104-107 interferon alpha 1 Homo sapiens 18-27 31640596-3 2019 However, the current standard of care (SOC) in Botswana remains PEGylated interferon-alpha (IFN-alpha) with ribavirin. Ribavirin 108-117 interferon alpha 1 Homo sapiens 92-101 30116347-7 2018 In conclusion, the present meta-analysis indicated that treatment with peg IFN + ribavirin or interferon only is associated with a wide range of neuropsychiatric side effects, including fatigue, mood disorders, anxiety, irritability, emotional ability and agitation. Ribavirin 81-90 interferon alpha 1 Homo sapiens 75-78 30450781-2 2019 In this phase 3b open-label study, we assessed changes in IFN-stimulated genes (ISGs) in non-cirrhotic treatment-naive or pegIFN/RBV-experienced HCV-GT1a-infected patients receiving paritaprevir/ritonavir/ombitasvir + dasabuvir + ribavirin (PrOD + R) for 12 weeks. Ribavirin 129-132 interferon alpha 1 Homo sapiens 58-61 30450781-2 2019 In this phase 3b open-label study, we assessed changes in IFN-stimulated genes (ISGs) in non-cirrhotic treatment-naive or pegIFN/RBV-experienced HCV-GT1a-infected patients receiving paritaprevir/ritonavir/ombitasvir + dasabuvir + ribavirin (PrOD + R) for 12 weeks. Ribavirin 230-239 interferon alpha 1 Homo sapiens 58-61 31081724-11 2019 Based on these findings, ribavirin-induced anti-RR autoantibody seems to be associated with a more frequent nonresponse to IFN-alpha/ribavirin therapy with a significant higher HCV viral load. Ribavirin 25-34 interferon alpha 1 Homo sapiens 123-132 31685739-1 2019 Recently, a clinical study using a Chronic Liver Disease Questionnaire (CLDQ) showed that ledipasvir/sofosbuvir (LDV/SOF)-treated patients" QOL was more favorable than that of IFN/ribavirin (RBV)-treated patients. Ribavirin 191-194 interferon alpha 1 Homo sapiens 176-189 30063745-14 2018 CONCLUSIONS: Our real-world results validate the efficacy of current GT3 IFN-free regimens suggesting that, among patients with severe disease, Peg/IFN/RBV experience and NS5A associated RASs are predictors of relapse. Ribavirin 152-155 interferon alpha 1 Homo sapiens 73-76 29851985-10 2018 CONCLUSIONS: Our study demonstrates that genetics of ITPA and IL28B may help identify patients protected from RBV-induced anemia when treated with IFN-free regimens. Ribavirin 110-113 interferon alpha 1 Homo sapiens 147-150 29920131-11 2018 We also found a significant difference in the relative expression of SOCS1 and SOCS3 in DAAs-treated and IFN/ribavirin (RBV)-treated and untreated individual. Ribavirin 120-123 interferon alpha 1 Homo sapiens 105-118 29851985-1 2018 BACKGROUND: Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV). Ribavirin 137-146 interferon alpha 1 Homo sapiens 194-197 29851985-1 2018 BACKGROUND: Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV). Ribavirin 147-150 interferon alpha 1 Homo sapiens 194-197 29851985-1 2018 BACKGROUND: Genetic variants of inosine triphosphatase (ITPA) that confer reduced ITPase activity are associated with protection against ribavirin(RBV)-induced hemolytic anemia in peginterferon(IFN)/RBV-based treatment of hepatitis C virus (HCV). Ribavirin 199-202 interferon alpha 1 Homo sapiens 194-197 29851985-4 2018 RBV has been an important component of IFN-containing regimens, and is currently recommended in combination with several IFN-free regimens for treatment of harder to cure HCV infections. Ribavirin 0-3 interferon alpha 1 Homo sapiens 39-42 29851985-5 2018 AIM: To evaluate whether genetic variations that reduce ITPase activity impact RBV-induced anemia in IFN-free/RBV regimens. Ribavirin 79-82 interferon alpha 1 Homo sapiens 101-104 29559835-2 2018 Currently, more than 90% of IFN-treated patients show a sustained virological response (SVR) when also treated with ribavirin and/or a protease inhibitor. Ribavirin 116-125 interferon alpha 1 Homo sapiens 28-31 29272349-7 2018 By the end of treatment, patients receiving IFN-containing regimens experienced significant decreases in most PRO domains (-4.5 to -28.7 on a 0-100 scale), while subjects treated with IFN-free RBV-containing regimens had a modest impairment (-2.3 to -8.9) (P <= .01). Ribavirin 193-196 interferon alpha 1 Homo sapiens 184-187 29540601-17 2018 Currently, off-label use of ribavirin (RBV) and polyethylene glycol-interferon (PEG-IFN) as antiviral therapy has shown promising results in both acute and chronic hepatitis E patients; however, the teratogenicity of RBV limits its use during pregnancy, while alpha IFN (IFN-alpha) increases the risk of transplant rejections. Ribavirin 28-37 interferon alpha 1 Homo sapiens 266-269 29540601-17 2018 Currently, off-label use of ribavirin (RBV) and polyethylene glycol-interferon (PEG-IFN) as antiviral therapy has shown promising results in both acute and chronic hepatitis E patients; however, the teratogenicity of RBV limits its use during pregnancy, while alpha IFN (IFN-alpha) increases the risk of transplant rejections. Ribavirin 28-37 interferon alpha 1 Homo sapiens 271-280 29540601-17 2018 Currently, off-label use of ribavirin (RBV) and polyethylene glycol-interferon (PEG-IFN) as antiviral therapy has shown promising results in both acute and chronic hepatitis E patients; however, the teratogenicity of RBV limits its use during pregnancy, while alpha IFN (IFN-alpha) increases the risk of transplant rejections. Ribavirin 217-220 interferon alpha 1 Homo sapiens 84-87 29664167-5 2018 Despite receiving treatment with ribavirin plus IFN, the case fatality rate was as high as 71% in the IFN-treatment group and exactly the same in patients who received supportive treatment only. Ribavirin 33-42 interferon alpha 1 Homo sapiens 102-105 29293991-6 2018 Subjects receiving IFN-free RBV-containing regimens had significant but smaller PRO decreases, again similar in the OST and non-OST groups. Ribavirin 28-31 interferon alpha 1 Homo sapiens 19-23 29293991-7 2018 Finally, subjects treated with regimens free of both IFN and RBV (IFN/RBV-free) showed improvements in nearly all PROs during treatment, with improvements more pronounced in OST recipients. Ribavirin 61-64 interferon alpha 1 Homo sapiens 66-78 28315743-8 2017 Considering a pharmacogenetic-guided approach, dual therapy with PEG-IFN and RBV can be considered a reliable option for patients ineligible for IFN-free treatments, who are motivated and well informed about all the aspects related to PEG-IFN administration. Ribavirin 77-80 interferon alpha 1 Homo sapiens 145-148 29039351-6 2017 During therapeutic regimens combined with ribavirin, destructive thyroiditis with typical biphasic course is more common than in IFN-alpha monotherapy. Ribavirin 42-51 interferon alpha 1 Homo sapiens 129-138 28506030-9 2017 Conclusions: Simeprevir-based triple therapy with reduced doses of PEG-IFN and ribavirin was safe and effective for IFN ineligible patients infected with genotype 1b HCV. Ribavirin 79-88 interferon alpha 1 Homo sapiens 116-119 28315743-8 2017 Considering a pharmacogenetic-guided approach, dual therapy with PEG-IFN and RBV can be considered a reliable option for patients ineligible for IFN-free treatments, who are motivated and well informed about all the aspects related to PEG-IFN administration. Ribavirin 77-80 interferon alpha 1 Homo sapiens 145-148 28496530-9 2017 Our results call for additional large studies and/or meta-analysis of all currently available data to examine the role of MxA nt-88 SNP in predicting response to PegIFN and ribavirin in patients with IFN-alpha naive HCV genotype 4. Ribavirin 173-182 interferon alpha 1 Homo sapiens 200-209 28036111-7 2017 IFNL4 expression was associated with non-response to PEG-IFN/ribavirin therapy. Ribavirin 61-70 interferon alpha 1 Homo sapiens 0-3 27896573-1 2017 The human immunodeficiency virus (HIV), hepatitis C virus (HCV), and the treatment of HCV with pegylated interferon and ribavirin (IFN/RBV) have been associated with neurocognitive and psychiatric abnormalities. Ribavirin 120-129 interferon alpha 1 Homo sapiens 131-134 28233734-7 2017 Prospective studies assessing the usefulness of RBV in the era of new IFN-free combinations are needed. Ribavirin 48-51 interferon alpha 1 Homo sapiens 70-73 27027531-0 2017 IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. AIM: Older patients with chronic hepatitis C have a lower virological response to interferon (IFN)-based treatments compared to younger patients. Ribavirin 72-81 interferon alpha 1 Homo sapiens 0-3 26921346-4 2016 First, IFN-alpha exerts a rapid, antiproliferative and proapoptotic effect in vitro and in vivo, as early as after 2 d of pegylated IFN/ribavirin therapy in patients with chronic hepatitis C. Such activities result in the decline, at d 2, in circulating regulatory T cell frequency and specifically of the activated regulatory T cell subset. Ribavirin 136-145 interferon alpha 1 Homo sapiens 7-16 28125694-5 2017 PATIENTS AND METHODS: Eighty-seven GT4 treatment-naive or -Interferon (IFN) ribavirin (RBV) experienced patients treated with sofosbuvir and simeprevir +/- ribavirin (RBV) were enrolled in this cohort study (41% severe fibrosis, 59% cirrhosis). Ribavirin 76-85 interferon alpha 1 Homo sapiens 71-74 29733167-5 2017 It was shown that in the case of treatment with Peg-IFN-alpha in combination with ribavirin, a significant decrease in the number of white blood cells, neutrophils and platelets prevailed in patients with HCV-monoinfected genotype 1b in the F0-F2 stages (2,8-8,6 kPa) at METAVIR. Ribavirin 82-91 interferon alpha 1 Homo sapiens 52-61 27857890-2 2016 The treatment typically involves a combination of interferon-alpha (IFN-alpha) and ribavirin (RBV) therapy; however, the use of IFN-alpha is well documented to be associated with thyroid disease, the most common autoimmune disorder associated with IFN-alpha. Ribavirin 83-92 interferon alpha 1 Homo sapiens 128-137 27857890-2 2016 The treatment typically involves a combination of interferon-alpha (IFN-alpha) and ribavirin (RBV) therapy; however, the use of IFN-alpha is well documented to be associated with thyroid disease, the most common autoimmune disorder associated with IFN-alpha. Ribavirin 83-92 interferon alpha 1 Homo sapiens 128-137 26921346-4 2016 First, IFN-alpha exerts a rapid, antiproliferative and proapoptotic effect in vitro and in vivo, as early as after 2 d of pegylated IFN/ribavirin therapy in patients with chronic hepatitis C. Such activities result in the decline, at d 2, in circulating regulatory T cell frequency and specifically of the activated regulatory T cell subset. Ribavirin 136-145 interferon alpha 1 Homo sapiens 7-10 26787701-6 2016 Furthermore, different IFN-alpha subtypes were also able to block viral replication in combination with ribavirin. Ribavirin 104-113 interferon alpha 1 Homo sapiens 23-32 27376688-1 2016 BACKGROUND: Triple therapy with Pegylated-Interferon alpha (PEG-IFNalpha)/Ribavirin (RBV) and Boceprevir (Boc) or Telaprevir (Tel) significantly improved sustained virological response (SVR) rates for patients with genotype 1 HCV infection compared to PEG-IFNalpha/RBV alone (dual therapy). Ribavirin 74-83 interferon alpha 1 Homo sapiens 256-264 27376688-1 2016 BACKGROUND: Triple therapy with Pegylated-Interferon alpha (PEG-IFNalpha)/Ribavirin (RBV) and Boceprevir (Boc) or Telaprevir (Tel) significantly improved sustained virological response (SVR) rates for patients with genotype 1 HCV infection compared to PEG-IFNalpha/RBV alone (dual therapy). Ribavirin 265-268 interferon alpha 1 Homo sapiens 64-72 26750805-7 2016 RBV-induced anemia was independently correlated with SLC29A1 rs760370 AA genotype (OR, 2.90; 95% CI, 1.29-6.54, P = 0.010), and the severity of IFN-induced thrombocytopenia was related to GG genotype (OR, 4.98; 95% CI, 1.27-19.61; P = 0.021); the detected effects held true for HCV-2a patients but weakened in HCV-1b patients. Ribavirin 0-3 interferon alpha 1 Homo sapiens 144-147 27399090-5 2016 Already during treatment, IFN/RBV-free therapy improved physical health (PCS: 41.4 +- 9.7 vs. 47.0 +- 11.2; P < 0.01) and reduced fatigue (37.8 +- 14.0 vs. 31.9 +- 15.2; P = 0.01), whereas we observed a substantial worsening of both factors in patients treated with BOC/PEGIFN/RBV. Ribavirin 280-283 interferon alpha 1 Homo sapiens 26-29 27275462-2 2016 This study aimed to evaluate IFN-induced ophthalmological manifestations in patients receiving PEGylated interferon (PEG IFN) and ribavirin (RBV) and to assess the effect of IFN duration, response and systemic risk factors on the severity. Ribavirin 130-139 interferon alpha 1 Homo sapiens 29-32 27275462-2 2016 This study aimed to evaluate IFN-induced ophthalmological manifestations in patients receiving PEGylated interferon (PEG IFN) and ribavirin (RBV) and to assess the effect of IFN duration, response and systemic risk factors on the severity. Ribavirin 141-144 interferon alpha 1 Homo sapiens 29-32 26082258-0 2016 Ribavirin restores IFNalpha responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Ribavirin 0-9 interferon alpha 1 Homo sapiens 19-27 26082258-0 2016 Ribavirin restores IFNalpha responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Ribavirin 0-9 interferon alpha 1 Homo sapiens 95-105 26082258-1 2016 OBJECTIVES: Caveats in the understanding of ribavirin (RBV) mechanisms of action has somehow prevented the development of better analogues able to further improve its therapeutic contribution in interferon (IFN)-based and direct antiviral agent-based regimens for chronic HCV or other indications. Ribavirin 44-53 interferon alpha 1 Homo sapiens 195-205 26082258-1 2016 OBJECTIVES: Caveats in the understanding of ribavirin (RBV) mechanisms of action has somehow prevented the development of better analogues able to further improve its therapeutic contribution in interferon (IFN)-based and direct antiviral agent-based regimens for chronic HCV or other indications. Ribavirin 44-53 interferon alpha 1 Homo sapiens 207-210 26082258-1 2016 OBJECTIVES: Caveats in the understanding of ribavirin (RBV) mechanisms of action has somehow prevented the development of better analogues able to further improve its therapeutic contribution in interferon (IFN)-based and direct antiviral agent-based regimens for chronic HCV or other indications. Ribavirin 55-58 interferon alpha 1 Homo sapiens 195-205 26082258-1 2016 OBJECTIVES: Caveats in the understanding of ribavirin (RBV) mechanisms of action has somehow prevented the development of better analogues able to further improve its therapeutic contribution in interferon (IFN)-based and direct antiviral agent-based regimens for chronic HCV or other indications. Ribavirin 55-58 interferon alpha 1 Homo sapiens 207-210 26082258-2 2016 Here, we describe a new mechanism by which RBV modulates IFN-stimulated genes (ISGs) and contributes to restore hepatic immune responsiveness. Ribavirin 43-46 interferon alpha 1 Homo sapiens 57-60 26082258-5 2016 RESULTS: RBV decreases the mRNA levels of several abnormally preactivated ISGs in patients with HCV, who are non-responders to IFN therapy. Ribavirin 9-12 interferon alpha 1 Homo sapiens 127-130 26082258-7 2016 G9a pharmacological blockade abolishes RBV-induced ISG downregulation and severely impairs RBV ability to potentiate IFN antiviral action and induction of ISGs following HCV infection of primary human hepatocytes. Ribavirin 91-94 interferon alpha 1 Homo sapiens 117-120 26082258-8 2016 CONCLUSIONS: RBV-induced epigenetic changes, leading to decreased ISG expression, restore an IFN-responsive hepatic environment in patients with HCV, which may also prove useful in IFN-free regimens. Ribavirin 13-16 interferon alpha 1 Homo sapiens 93-96 26082258-8 2016 CONCLUSIONS: RBV-induced epigenetic changes, leading to decreased ISG expression, restore an IFN-responsive hepatic environment in patients with HCV, which may also prove useful in IFN-free regimens. Ribavirin 13-16 interferon alpha 1 Homo sapiens 181-184 26945356-3 2016 The aim of this study was to assess the impact of IFN-free RBV-free sofosbuvir (SOF)-based regimens on PROs in CH-C patients of Asian ancestry. Ribavirin 59-62 interferon alpha 1 Homo sapiens 50-53 26825683-4 2016 Despite this, these participants experienced significant PRO improvement during treatment with IFN-free RBV-free regimens (up to +8.0%, P < .001), similar to improvements in younger participants. Ribavirin 104-107 interferon alpha 1 Homo sapiens 95-98 26825683-5 2016 In contrast, participants aged 65 and older experienced substantial decline in PROs while receiving IFN- or RBV-containing regimens (up to -18.9% in IFN + SOF + RBV, -10.4% in IFN-free SOF+RBV, P < .001), and some were greater than in the younger group. Ribavirin 108-111 interferon alpha 1 Homo sapiens 149-152 25914454-3 2015 Currently, interferon (IFN)-based regimens can be used in dual-agent regimens with ribavirin, in triple-agent antiviral strategies with direct-acting antivirals (e.g., protease inhibitors telaprevir or boceprevir), or before transplant in compensated patients to reduce HCV viral load to prevent or reduce the risk of post-LT recurrence and complications; they cannot be used in patients with decompensated cirrhosis. Ribavirin 83-92 interferon alpha 1 Homo sapiens 11-21 27170384-6 2016 In the setting of liver transplantation, with an accelerated course of hepatitis C, previous IFN-RBV treatments were poorly tolerated and attained low SVR rates. Ribavirin 97-100 interferon alpha 1 Homo sapiens 93-96 26684004-1 2015 BACKGROUND: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-alpha plus ribavirin combination therapy (PEG-IFNalpha/RBV). Ribavirin 218-227 interferon alpha 1 Homo sapiens 253-261 26684004-1 2015 BACKGROUND: Amino acid (aa) 70 substitution (R70Q/H) in the core protein of hepatitis C virus (HCV) genotype 1b has been shown to be one of the key factors in determining resistance for pegylated interferon-alpha plus ribavirin combination therapy (PEG-IFNalpha/RBV). Ribavirin 262-265 interferon alpha 1 Homo sapiens 253-261 26177560-3 2015 In 2009, a genome wide association study (GWAS) revealed that genetic variants in close proximity to the IL28B (IFNL3) gene predicted greater likelihood of achieving sustained virological response (SVR) following treatment with pegylated IFN-alpha (peg INF-alpha) and ribavirin. Ribavirin 268-277 interferon alpha 1 Homo sapiens 238-247 25501286-2 2015 The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. Ribavirin 187-196 interferon alpha 1 Homo sapiens 47-50 25501286-2 2015 The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. Ribavirin 187-196 interferon alpha 1 Homo sapiens 85-88 25501286-2 2015 The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. Ribavirin 187-196 interferon alpha 1 Homo sapiens 85-88 25501286-2 2015 The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. Ribavirin 198-201 interferon alpha 1 Homo sapiens 47-50 25501286-2 2015 The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. Ribavirin 198-201 interferon alpha 1 Homo sapiens 85-88 25501286-2 2015 The single nucleotide polymorphisms within the IFNL3 gene, which encodes interferon (IFN)-lambda(3), are strongly associated with the response to pegylated IFN-alpha (PEG-IFN-alpha) plus ribavirin (RBV) therapy in chronic hepatitis C (C-CH) patients. Ribavirin 198-201 interferon alpha 1 Homo sapiens 85-88 25963122-1 2015 Aim: Pegylated-interferon/ribavirin/simeprevir (PEG-IFN/RBV/SMV) combination therapy is widely used for hepatitis C virus (HCV) treatment after liver transplantation (LT). Ribavirin 26-35 interferon alpha 1 Homo sapiens 52-55 24961662-1 2015 AIM: The efficacy and safety of simeprevir in combination with peginterferon-alpha-2b and ribavirin (PEG IFN-alpha-2b/RBV) were investigated in patients infected with hepatitis C virus (HCV) genotype 1 who were treatment-naive or had previously received interferon (IFN)-based therapy. Ribavirin 90-99 interferon alpha 1 Homo sapiens 105-108 26118427-11 2015 CONCLUSIONS: ALV plus RBV represents an effective IFN-free option for a proportion of patients with HCV genotype 2 or 3 infections, with high SVR rates for patients with early viral clearance. Ribavirin 22-25 interferon alpha 1 Homo sapiens 50-53 25382001-2 2015 Interferon alpha (IFNalpha) sensitivity in liver and IL28B genotype has been identified as important determinants of HCV clearance in the setting of pegylated interferon/ribavirin treatment. Ribavirin 170-179 interferon alpha 1 Homo sapiens 18-26 25914454-3 2015 Currently, interferon (IFN)-based regimens can be used in dual-agent regimens with ribavirin, in triple-agent antiviral strategies with direct-acting antivirals (e.g., protease inhibitors telaprevir or boceprevir), or before transplant in compensated patients to reduce HCV viral load to prevent or reduce the risk of post-LT recurrence and complications; they cannot be used in patients with decompensated cirrhosis. Ribavirin 83-92 interferon alpha 1 Homo sapiens 23-26 25515861-5 2015 Furthermore, rs2305482 genotype was associated with the doses of pegylated interferon (PEG-IFN) that could be tolerated in hepatitis C virus genotype 1-infected patients treated with PEG-IFN plus ribavirin, but not with treatment efficacy. Ribavirin 196-205 interferon alpha 1 Homo sapiens 91-94 25650729-9 2015 CONCLUSIONS: Concentration-guided RBV dosing with darbepoetin support substantially improves tolerance and offers high adherence to a full peg-IFN and RBV treatment course in patients with post-transplant HCV relapse. Ribavirin 34-37 interferon alpha 1 Homo sapiens 143-146 25920094-3 2015 Successive improvements in IFN-alpha-based therapy (dose finding, pegylation, addition of ribavirin) increased the rates of sustained virologic response, i.e. the rates of curing HCV infection. Ribavirin 90-99 interferon alpha 1 Homo sapiens 27-30 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 64-73 interferon alpha 1 Homo sapiens 180-188 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 64-73 interferon alpha 1 Homo sapiens 223-231 25548485-6 2014 In particular, patients who received combined peginterferon alfa-2b and ribavirin had significantly higher mean VAS scores than those receiving peginterferon alfa-2a or no IFN treatment. Ribavirin 72-81 interferon alpha 1 Homo sapiens 172-175 25445343-1 2015 BACKGROUND: It has been suggested that HCV proteins, core, NS3/4A, NS4B, and NS5A, contribute to the resistance of HCV to IFN and ribavirin (RBV) treatments. Ribavirin 141-144 interferon alpha 1 Homo sapiens 122-125 25624738-1 2015 The effectiveness of hepatitis C treatment has improved with the development of interferon (IFN), and it has drastically improved with the development of peg-interferon-alpha (PEG-IFN) in combination with ribavirin (RBV) and, more recently, with the addition of a protease inhibitor. Ribavirin 216-219 interferon alpha 1 Homo sapiens 180-183 26078754-1 2015 Pegylated interferon-alpha and ribavirin (PEG-IFN/RBV) is widely used to treat chronic hepatitis C virus infection with notorious adverse reactions since the broad expression of IFN-alpha receptors on all nucleated cells. Ribavirin 31-40 interferon alpha 1 Homo sapiens 178-187 26078754-1 2015 Pegylated interferon-alpha and ribavirin (PEG-IFN/RBV) is widely used to treat chronic hepatitis C virus infection with notorious adverse reactions since the broad expression of IFN-alpha receptors on all nucleated cells. Ribavirin 50-53 interferon alpha 1 Homo sapiens 178-187 25529083-2 2015 Second wave direct acting antivirals such as sofosbuvir, simeprevir and daclatasvir can be combined with pegylated interferon alpha and ribavirin (PEG-IFN/RBV) as triple therapy in patients with hepatitis C virus (HCV) infection. Ribavirin 136-145 interferon alpha 1 Homo sapiens 151-154 25529083-4 2015 A PEG-IFN/RBV-based regimen with simeprevir or daclatasvir is based on response-guided therapy and its efficacy depends on predictors of response to IFN. Ribavirin 10-13 interferon alpha 1 Homo sapiens 149-152 27442378-3 2015 The next two decades saw a series of incremental improvements of the IFN therapies by extending the duration of therapy, using IFN in combination with oral ribavirin, using pegylated IFN with ribavirin, and most recently adding oral compounds that inhibit the HCV replication (directly acting antivirals - DAAs) to that regimen. Ribavirin 156-165 interferon alpha 1 Homo sapiens 69-72 27442378-3 2015 The next two decades saw a series of incremental improvements of the IFN therapies by extending the duration of therapy, using IFN in combination with oral ribavirin, using pegylated IFN with ribavirin, and most recently adding oral compounds that inhibit the HCV replication (directly acting antivirals - DAAs) to that regimen. Ribavirin 192-201 interferon alpha 1 Homo sapiens 69-72 25664085-10 2014 IFN binds to its receptor on the infected hepatocyte surface during Peg-IFNalpha and ribavirin treatment. Ribavirin 85-94 interferon alpha 1 Homo sapiens 0-3 25355997-6 2014 The IFNalpha was the most active compound, with an average IC50 (50% inhibitory concentration) value lower than the IC50 of the RBV. Ribavirin 128-131 interferon alpha 1 Homo sapiens 4-12 25364884-1 2014 BACKGROUND: The interferon (IFN)-free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infection for patients ineligible for IFN. Ribavirin 64-73 interferon alpha 1 Homo sapiens 28-31 25364884-1 2014 BACKGROUND: The interferon (IFN)-free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infection for patients ineligible for IFN. Ribavirin 64-73 interferon alpha 1 Homo sapiens 206-209 25171028-4 2014 Our aim was to evaluate treatment outcome and host/viral factors on SVR in HCV-4 patients treated with pegylated interferon and ribavirin (PEG IFN+RBV) in a systematic and quantitative manner. Ribavirin 128-137 interferon alpha 1 Homo sapiens 143-150 25705565-15 2014 Collectively, our study led to identification of important correlates of IFN/RBV treatment response in HIV-1/HCV co-infected individuals. Ribavirin 77-80 interferon alpha 1 Homo sapiens 73-76 25326107-1 2014 Treatment of hepatitis C virus (HCV) with pegylated interferon and ribavirin (IFN/RBV) can be associated with neuropsychiatric side effects, which may necessitate dose reductions or treatment discontinuation. Ribavirin 67-76 interferon alpha 1 Homo sapiens 78-81 25473172-4 2014 Ribavirin (RBV) monotherapy has been shown to decrease inflammation in liver of patients with chronic hepatitis C. Sustained virological response (SVR) is significantly higher when IFN is combined with RBV in chronic HCV (cHCV) infection. Ribavirin 0-9 interferon alpha 1 Homo sapiens 181-184 25473172-4 2014 Ribavirin (RBV) monotherapy has been shown to decrease inflammation in liver of patients with chronic hepatitis C. Sustained virological response (SVR) is significantly higher when IFN is combined with RBV in chronic HCV (cHCV) infection. Ribavirin 11-14 interferon alpha 1 Homo sapiens 181-184 24700342-0 2014 Ribavirin improves the IFN-gamma response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Ribavirin 0-9 interferon alpha 1 Homo sapiens 23-26 24845459-9 2014 In conclusion, this study showed that the temporal kinetics of IFN-alpha + ribavirin-induced humoral autoimmune response to IMPDH2 exhibited a considerably delayed pace of increase in antibody levels and avidity as well as in isotype class switch in comparison with a conventional humoral response to infectious agents. Ribavirin 75-84 interferon alpha 1 Homo sapiens 63-72 24700342-0 2014 Ribavirin improves the IFN-gamma response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Ribavirin 0-9 interferon alpha 1 Homo sapiens 69-72 24700342-1 2014 UNLABELLED: Ribavirin (RBV) is an important component of interferon (IFN)-based and direct antiviral treatment regimens for hepatitis C virus (HCV) infection. Ribavirin 12-21 interferon alpha 1 Homo sapiens 69-72 24700342-1 2014 UNLABELLED: Ribavirin (RBV) is an important component of interferon (IFN)-based and direct antiviral treatment regimens for hepatitis C virus (HCV) infection. Ribavirin 23-26 interferon alpha 1 Homo sapiens 69-72 24700342-2 2014 Immunomodulation, in particular improvement of the host IFN response, has been proposed as RBV"s mechanism of action. Ribavirin 91-94 interferon alpha 1 Homo sapiens 56-59 24700342-7 2014 In vitro or in vivo exposure of NK cells to RBV improved the pSTAT4 (P < 0.01) but not pSTAT1 response of NK cells to subsequent stimulation with IFN-alpha. Ribavirin 44-47 interferon alpha 1 Homo sapiens 149-158 24700342-10 2014 CONCLUSION: RBV enhances the pSTAT4 and IFN-gamma response of NK cells to IFN-alpha-stimulation. Ribavirin 12-15 interferon alpha 1 Homo sapiens 74-83 24957263-1 2014 Ribavirin is a broad spectrum antiviral that increases the response rate in chronic hepatitis C patients when administered in combination with IFNalpha. Ribavirin 0-9 interferon alpha 1 Homo sapiens 143-151 24848437-4 2014 However, an IFN-free combination (sofosbuvir and ribavirin) has been recently approved for genotypes 2 and 3 patients with many other drugs in preclinical and clinical development. Ribavirin 49-58 interferon alpha 1 Homo sapiens 12-15 24994464-1 2014 PROPOSE: IL28B polymorphisms rs12979860 CC genotype was associated to protection of HCV infection and sustained virological response (SVR) in HCV infected patients treated with pegIFNalpha/ribavirin (IFNalpha/RIB), however, this polymorphism frequency varies depending on genetic components. Ribavirin 189-198 interferon alpha 1 Homo sapiens 180-188 25132867-3 2014 Thus, natural IFN-beta plus ribavirin therapy may be a treatment option for patients with poor tolerance to IFN-alpha or pegIFN-alpha treatments. Ribavirin 28-37 interferon alpha 1 Homo sapiens 108-117 24793175-1 2014 CASE PRESENTATION: Here, we present a Japanese child with chronic hepatitis C with fibrosis, who did not respond to Peg-IFN alpha-2b but responded to Peg-IFN alpha-2a with ribavirin, accompanied with fluvastatin. Ribavirin 172-181 interferon alpha 1 Homo sapiens 154-157 25077851-7 2014 Presence of certain depressive symptoms i.e., presence of little interest or pleasure in doing things, feeling tired or having little energy, poor appetite, social withdrawal and work inhibition at the baseline were associated with development of depression during the course of pegylated IFN-alpha plus ribavirin therapy. Ribavirin 304-313 interferon alpha 1 Homo sapiens 289-298 25077851-8 2014 CONCLUSION: Depressive symptoms in patients with pegylated IFN-alpha and ribavirin induced MDE are influenced by the symptoms of depression prior to starting of pegylated IFN-alpha and ribavirin combination. Ribavirin 73-82 interferon alpha 1 Homo sapiens 171-180 25077851-8 2014 CONCLUSION: Depressive symptoms in patients with pegylated IFN-alpha and ribavirin induced MDE are influenced by the symptoms of depression prior to starting of pegylated IFN-alpha and ribavirin combination. Ribavirin 185-194 interferon alpha 1 Homo sapiens 59-68 24657484-10 2014 CONCLUSIONS: A higher percentage of patients with chronic HCV infection who received immunotherapy with TG4040 followed by TG4040 and PEG-IFNalpha/RBV achieved a cEVR compared with patients who received only PEG-IFNalpha/RBV therapy. Ribavirin 147-150 interferon alpha 1 Homo sapiens 138-146 24677184-1 2014 UNLABELLED: Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)-ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks. Ribavirin 304-313 interferon alpha 1 Homo sapiens 227-230 24677184-1 2014 UNLABELLED: Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)-ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks. Ribavirin 319-322 interferon alpha 1 Homo sapiens 227-230 24621321-0 2014 Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-alpha-2a with ribavirin therapy: a case report. Ribavirin 135-144 interferon alpha 1 Homo sapiens 104-126 24488144-4 2014 Population-wide resistance and presence of IFN-resistant variants were highly associated with pegylated IFN-alpha2a/ribavirin treatment outcome at week 12 (P = 3.78 x 10(-5) and 0.0114, respectively). Ribavirin 116-125 interferon alpha 1 Homo sapiens 43-46 24367041-1 2014 Response to pegylated interferon-alpha and ribavirin (IFN-alpha/RBV) treatment for chronic hepatitis C virus (HCV) infection is influenced by host genetic factors, but their role for IFN-alpha-free, direct-acting antiviral (DAA) regimens is unclear. Ribavirin 43-52 interferon alpha 1 Homo sapiens 54-63 24367041-1 2014 Response to pegylated interferon-alpha and ribavirin (IFN-alpha/RBV) treatment for chronic hepatitis C virus (HCV) infection is influenced by host genetic factors, but their role for IFN-alpha-free, direct-acting antiviral (DAA) regimens is unclear. Ribavirin 43-52 interferon alpha 1 Homo sapiens 183-192 24367041-3 2014 We report that in patients treated with the DAA sofosbuvir along with RBV, IFNL4-DeltaG is associated with slower early viral decay, due to slower loss of free virus (P = .039) and decreased drug efficacy (P = .048), suggesting functional relevance of IFN-lambda4 in IFN-alpha-free DAA therapies. Ribavirin 70-73 interferon alpha 1 Homo sapiens 267-276 25097047-8 2014 Moreover, chronic HCV patients treated with IFN and ribavirin had significantly lower levels of C3 and C4 compared with patients naive to IFN and ribavirin treatment. Ribavirin 52-61 interferon alpha 1 Homo sapiens 138-141 25097047-8 2014 Moreover, chronic HCV patients treated with IFN and ribavirin had significantly lower levels of C3 and C4 compared with patients naive to IFN and ribavirin treatment. Ribavirin 146-155 interferon alpha 1 Homo sapiens 44-47 24329856-1 2014 Ribavirin amplifies the interferon-alpha (IFN) signalling cascade. Ribavirin 0-9 interferon alpha 1 Homo sapiens 42-45 24022240-5 2014 In 2009, genome-wide association studies found the single-nucleotide polymorphisms, located near the host interleukin-28B (IL28B) gene that encodes IFN-lambda3, to be the best pretreatment predictor of virologic response to Peg-IFN and RBV therapy in chronic hepatitis C genotype 1 patients. Ribavirin 236-239 interferon alpha 1 Homo sapiens 148-151 24022240-5 2014 In 2009, genome-wide association studies found the single-nucleotide polymorphisms, located near the host interleukin-28B (IL28B) gene that encodes IFN-lambda3, to be the best pretreatment predictor of virologic response to Peg-IFN and RBV therapy in chronic hepatitis C genotype 1 patients. Ribavirin 236-239 interferon alpha 1 Homo sapiens 228-231 24670522-9 2014 In sensitivity analyses, IFN-free treatment attaining 90% SVR had an ICER less than $100 000/QALY compared with "PEG/RBV trial" when its cost was $109 000 or less (125% of the cost of PEG/RBV/TVR). Ribavirin 188-191 interferon alpha 1 Homo sapiens 25-28 25369007-11 2014 The analysis of results from TaqMan SNP Genotyping has been shown that two SNPs (Ex4-30G>C and Ivs1-4640 G>A) of IFNAR1 and IFNAR2 didn"t show any relationship with response to combined therapy in subjects affected with chronic hepatitis C who have treated with peg-IFN-alpha and Ribavirin. Ribavirin 286-295 interferon alpha 1 Homo sapiens 119-122 24584067-1 2014 BACKGROUND: Amino acid variations in several HCV genomic regions have been reported to be associated with response to interferon (IFN)-alpha plus ribavirin (RBV) combination therapy. Ribavirin 157-160 interferon alpha 1 Homo sapiens 118-140 25548683-11 2014 IFNL4 ss469415590 variant and HCV viral loads or IFNL4 ss469415590 variant and early virological response were better predictors of SVR in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively. Ribavirin 174-183 interferon alpha 1 Homo sapiens 0-3 24171456-1 2014 Enhanced endogenous interferon (IFN) stimulated gene (ISG) signature has been associated with nonresponsiveness to hepatitis C treatment using pegylated-IFNalpha (pegIFNalpha) and ribavirin (RBV) in human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfected patients. Ribavirin 180-189 interferon alpha 1 Homo sapiens 32-35 24171456-1 2014 Enhanced endogenous interferon (IFN) stimulated gene (ISG) signature has been associated with nonresponsiveness to hepatitis C treatment using pegylated-IFNalpha (pegIFNalpha) and ribavirin (RBV) in human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfected patients. Ribavirin 191-194 interferon alpha 1 Homo sapiens 32-35 24329856-2 2014 As ribavirin needs 4 weeks to reach steady state, ribavirin priming may optimize hepatic IFN sensitivity before starting a pegylated (PEG)-IFN/ribavirin combination therapy. Ribavirin 50-59 interferon alpha 1 Homo sapiens 89-92 24329856-2 2014 As ribavirin needs 4 weeks to reach steady state, ribavirin priming may optimize hepatic IFN sensitivity before starting a pegylated (PEG)-IFN/ribavirin combination therapy. Ribavirin 50-59 interferon alpha 1 Homo sapiens 89-92 24145541-3 2014 IFN-alpha showed a moderate but significant synergism with ribavirin. Ribavirin 59-68 interferon alpha 1 Homo sapiens 0-9 23942001-2 2013 The aim of our study was retrospective evaluation of treatment efficacy using pegylated interferon (IFN)-alpha2b with ribavirin in children and adolescents with chronic hepatitis C, both treatment naive and re-treated. Ribavirin 118-127 interferon alpha 1 Homo sapiens 88-110 24254131-6 2013 In particular, an IFN sparing regimen of sofosbuvir/RBV may become available in 2014. Ribavirin 52-55 interferon alpha 1 Homo sapiens 18-21 30534284-0 2013 Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C. The therapeutic effect of interferon (IFN) on chronic hepatitis C and its adverse effects have been well documented. Ribavirin 46-55 interferon alpha 1 Homo sapiens 129-139 24579307-5 2013 The results showed that single nucleotide polymorphisms (SNPs) of the IL28B gene, which encodes protein IFN-lambda3, are associated with viral clearance and treatment effectiveness of HCV patients who were cured by PEG-IFNalpha combined with ribavirin (RBV). Ribavirin 253-256 interferon alpha 1 Homo sapiens 219-227 24204676-1 2013 BACKGROUND: Antidepressants are effective in treating interferon-alpha/ribavirin (IFN-alpha/RBV)-associated depression during or after treatment of chronic hepatitis C (CHC). Ribavirin 71-80 interferon alpha 1 Homo sapiens 82-91 24579307-5 2013 The results showed that single nucleotide polymorphisms (SNPs) of the IL28B gene, which encodes protein IFN-lambda3, are associated with viral clearance and treatment effectiveness of HCV patients who were cured by PEG-IFNalpha combined with ribavirin (RBV). Ribavirin 242-251 interferon alpha 1 Homo sapiens 219-227 30534284-0 2013 Sick sinus syndrome induced by interferon and ribavirin therapy in a patient with chronic hepatitis C. The therapeutic effect of interferon (IFN) on chronic hepatitis C and its adverse effects have been well documented. Ribavirin 46-55 interferon alpha 1 Homo sapiens 141-144 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 278-287 interferon alpha 1 Homo sapiens 164-167 23553458-2 2013 Traditional treatment with pegylated interferon plus ribavirin (peg-IFN + RBV) is very expensive and has a low rate of sustained virological response in coinfected patients, especially if they are infected with HCV genotype 1. Ribavirin 53-62 interferon alpha 1 Homo sapiens 68-71 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 278-287 interferon alpha 1 Homo sapiens 264-272 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 289-292 interferon alpha 1 Homo sapiens 164-167 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 289-292 interferon alpha 1 Homo sapiens 250-258 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 289-292 interferon alpha 1 Homo sapiens 264-272 26357605-1 2013 In a recent genome-wide association study, single nucleotide polymorphisms (SNPs) located near the interleukin-28B gene (IL28B), which encodes type III interferon (IFN) lambda3, were shown to be strongly associated with a viral response to pegylated IFNalpha (PEG-IFNalpha) and ribavirin (RBV) combination therapy and spontaneous viral clearance in patients chronically and acutely infected with hepatitis C virus (HCV), respectively. Ribavirin 278-287 interferon alpha 1 Homo sapiens 250-258 23216931-0 2013 Serum peptides, represented by complement 3f des-arginine, are useful for prediction of the response to pegylated interferon-alpha plus ribavirin in patients with chronic hepatitis C. AIM: Biomarkers predicting sustained virological response (SVR) to pegylated interferon-alpha plus ribavirin (PEG IFN-alpha/RBV) were investigated. Ribavirin 136-145 interferon alpha 1 Homo sapiens 298-307 23359491-11 2013 CONCLUSION: A 24-week response-guided combination regimen of mericitabine 1,000 mg BID plus Peg-IFNalpha-2a/RBV is well tolerated and more effective than a standard 48-week course of Peg-IFNalpha-2a/RBV. Ribavirin 108-111 interferon alpha 1 Homo sapiens 187-195 23359491-11 2013 CONCLUSION: A 24-week response-guided combination regimen of mericitabine 1,000 mg BID plus Peg-IFNalpha-2a/RBV is well tolerated and more effective than a standard 48-week course of Peg-IFNalpha-2a/RBV. Ribavirin 199-202 interferon alpha 1 Homo sapiens 96-104 23403428-2 2013 Viral RNA declines have been observed in the clinic for both alpha interferon-ribavirin (IFN-alpha-RBV) and IFN-RBV-free regimens that include DCV. Ribavirin 99-102 interferon alpha 1 Homo sapiens 89-98 23637397-8 2013 IFN-alpha-resistant populations displayed decreased sensitivity to a combination of IFN-alpha and ribavirin. Ribavirin 98-107 interferon alpha 1 Homo sapiens 0-9 23449803-7 2013 Furthermore, miR-27a enhanced in vitro interferon (IFN) signaling, and patients who expressed high levels of miR-27a in the liver showed a more favorable response to pegylated IFN and ribavirin combination therapy. Ribavirin 184-193 interferon alpha 1 Homo sapiens 33-55 23449803-7 2013 Furthermore, miR-27a enhanced in vitro interferon (IFN) signaling, and patients who expressed high levels of miR-27a in the liver showed a more favorable response to pegylated IFN and ribavirin combination therapy. Ribavirin 184-193 interferon alpha 1 Homo sapiens 51-54 23559897-1 2013 Ribavirin is an antiviral drug used in combination with pegylated interferon-alpha (IFN-alpha) for the treatment of hepatitis C virus (HCV) infection. Ribavirin 0-9 interferon alpha 1 Homo sapiens 84-93 23280583-7 2013 In conclusion, the data indicate that immune cells of responders and non-responders to IFN/RBV therapy exhibited significantly different virological and host gene expression profiles. Ribavirin 91-94 interferon alpha 1 Homo sapiens 87-90 23359634-0 2012 Evolution of viral RNA in a Chinese patient to interferon/ribavirin therapy for hepatitis C. OBJECTIVE: The combination of interferon (IFN) and ribavirin (RBV) is the standard therapy for hepatitis C virus (HCV) infection. Ribavirin 58-67 interferon alpha 1 Homo sapiens 135-138 24490062-4 2013 Relative mRNA expression of TLR3/RIG-I signaling genes involved in IFN- beta production was correlated with positive- and negative-strand HCV RNAs in pretreatment liver tissues responsive and nonresponsive to peginterferon and ribavirin for chronic hepatitis C genotype 1. Ribavirin 227-236 interferon alpha 1 Homo sapiens 67-70 24281016-7 2013 CONCLUSION: The NS5A sequence heterogeneity and IL28B SNP are useful factors to predict the sensitivity to PEG-IFN/RBV therapy in HCV-2a and HCV-2b infections. Ribavirin 115-118 interferon alpha 1 Homo sapiens 111-114 23359634-9 2012 In addition, each different response of chimeric replicon to IFN is most likely related to amino acid changes in or near the IFN-sensitivity determining region (ISDR) of NS5A during chronic infection and IFN/RBV therapy. Ribavirin 208-211 interferon alpha 1 Homo sapiens 61-64 29702891-7 2012 RESULTS: The total direct cost of hepatitis C treatment per patient with interferon alpha (IFN) plus ribavirin (RBV) was US $982.25, with peginterferon alpha (PEG) 2a 180 mug plus RBV was US $10,658.08, and with PEG 2b 120 mug plus RBV was US $12,597.63, taking into account entire treatment according to Brazilian guidelines and assuming that all patients completed full treatment. Ribavirin 180-183 interferon alpha 1 Homo sapiens 91-94 23020144-1 2012 BACKGROUND AND AIM: Recently, it has been suggested that single nucleotide polymorphisms (SNPs) in some cytokine genes may influence the production of the associated cytokines that affect the host immune response to pegylated interferon-alpha (Peg-IFN-alpha) with ribavirin (RBV) in hepatitis C virus (HCV) patients. Ribavirin 264-273 interferon alpha 1 Homo sapiens 248-257 23020144-1 2012 BACKGROUND AND AIM: Recently, it has been suggested that single nucleotide polymorphisms (SNPs) in some cytokine genes may influence the production of the associated cytokines that affect the host immune response to pegylated interferon-alpha (Peg-IFN-alpha) with ribavirin (RBV) in hepatitis C virus (HCV) patients. Ribavirin 275-278 interferon alpha 1 Homo sapiens 248-257 29702891-7 2012 RESULTS: The total direct cost of hepatitis C treatment per patient with interferon alpha (IFN) plus ribavirin (RBV) was US $982.25, with peginterferon alpha (PEG) 2a 180 mug plus RBV was US $10,658.08, and with PEG 2b 120 mug plus RBV was US $12,597.63, taking into account entire treatment according to Brazilian guidelines and assuming that all patients completed full treatment. Ribavirin 180-183 interferon alpha 1 Homo sapiens 91-94 22577043-4 2012 Those NS5A regions nearly coincided with the interferon (IFN) sensitivity-determining region (NS5A aa.2209-2248) and the IFN/RBV resistance-determining region (NS5A aa.2339-2379). Ribavirin 125-128 interferon alpha 1 Homo sapiens 121-124 23109451-3 2012 Our aim was to establish an association between three IL28B SNPs (rs8099917, rs12979860, and rs8103142) and the peg-IFNalpha/RBV treatment response in a Mexican population cohort with chronic HCV. Ribavirin 125-128 interferon alpha 1 Homo sapiens 116-124 22985631-6 2012 IFN-alpha synergistically regulated ERK and STAT3 phosphorylation with ribavirin, and up-regulated expression and phosphorylation of STAT1. Ribavirin 71-80 interferon alpha 1 Homo sapiens 0-9 22432893-1 2012 BACKGROUND AND AIM: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) influences viral response (VR) to interferon (IFN) therapy in patients with hepatitis C. We studied the relationship between VR and the IL28B polymorphism (rs8099917) in patients on long-term pegylated IFN plus ribavirin (PEGIFN/RBV) therapy for recurrent hepatitis C after living-donor liver transplantation (LDLT). Ribavirin 292-301 interferon alpha 1 Homo sapiens 127-130 22824093-1 2012 The addition of the broad-spectrum antiviral agent ribavirin (RBV), a synthetic guanosine analog, to interferon-alpha (IFNalpha) monotherapy has been a major breakthrough in the treatment of patients with hepatitis C virus (HCV), as it greatly improved treatment response rates. Ribavirin 51-60 interferon alpha 1 Homo sapiens 119-127 22824093-1 2012 The addition of the broad-spectrum antiviral agent ribavirin (RBV), a synthetic guanosine analog, to interferon-alpha (IFNalpha) monotherapy has been a major breakthrough in the treatment of patients with hepatitis C virus (HCV), as it greatly improved treatment response rates. Ribavirin 62-65 interferon alpha 1 Homo sapiens 119-127 22824093-2 2012 Although several mechanisms of action have been proposed for RBV"s antiviral activity, each with some experimental evidence, the precise mechanism by which it acts synergistically with IFNalpha has remained elusive. Ribavirin 61-64 interferon alpha 1 Homo sapiens 185-193 22899224-0 2012 Mutations in non-structural 5A and rapid viral response to pegylated interferon-alpha-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C. For patients chronically infected with hepatitis C virus (HCV), mutations in the non-structural 5A (NS5A) gene are important predictive factors for the response to interferon (IFN) therapy. Ribavirin 106-115 interferon alpha 1 Homo sapiens 403-406 22432893-1 2012 BACKGROUND AND AIM: Interleukin-28B (IL28B) single nucleotide polymorphism (SNP) influences viral response (VR) to interferon (IFN) therapy in patients with hepatitis C. We studied the relationship between VR and the IL28B polymorphism (rs8099917) in patients on long-term pegylated IFN plus ribavirin (PEGIFN/RBV) therapy for recurrent hepatitis C after living-donor liver transplantation (LDLT). Ribavirin 310-313 interferon alpha 1 Homo sapiens 127-130 22554247-1 2012 BACKGROUND AND AIM: The inosine triphosphatase (ITPA) genotype is associated with ribavirin-induced anemia and pegylated interferon alpha (PEG IFN-alpha)-induced platelet reduction during PEG IFN-alpha plus ribavirin combination therapy. Ribavirin 82-91 interferon alpha 1 Homo sapiens 192-201 22554247-1 2012 BACKGROUND AND AIM: The inosine triphosphatase (ITPA) genotype is associated with ribavirin-induced anemia and pegylated interferon alpha (PEG IFN-alpha)-induced platelet reduction during PEG IFN-alpha plus ribavirin combination therapy. Ribavirin 207-216 interferon alpha 1 Homo sapiens 143-152 25755419-1 2012 BACKGROUND: The single nucleotide polymorphism (SNP) of IL28B gene on chromosome 19, encoding for the interferon (IFN)-lambda-3 is strongly associated with treatment response to pegylated-IFN and ribavirin in patients infected with different genotypes of hepatitis C virus (HCV). Ribavirin 196-205 interferon alpha 1 Homo sapiens 114-117 22683884-1 2012 BACKGROUND: The rate of non-response to pegylated interferon plus ribavirin (peg-IFN+RBV) in HCV/HIV coinfected patients is higher than in HCV-monoinfected patients. Ribavirin 66-75 interferon alpha 1 Homo sapiens 81-84 22331604-1 2012 UNLABELLED: Recent studies have shown that a single-nucleotide polymorphism upstream of the interleukin-28B (IL28B) gene plays a major role in predicting therapeutic response in hepatitis C virus (HCV)-infected patients treated with pegylated interferon (PEG-IFN)/ribavirin. Ribavirin 264-273 interferon alpha 1 Homo sapiens 259-262 22863266-10 2012 Haemoglobin reductions <10 g/dL were less frequent with albIFN 900 and 1200 mug vs 1500 mug and Peg-IFNalpha-2a (P = 0.02), leading to fewer ribavirin dose reductions. Ribavirin 144-153 interferon alpha 1 Homo sapiens 103-111 22783042-5 2012 Over the past 20 years, IFN therapy has improved to more effectively eliminate the virus, progressing from single IFN therapy to combination therapy with ribavirin (RBV) and finally to pegylated IFN (PEG-IFN) therapy. Ribavirin 154-163 interferon alpha 1 Homo sapiens 24-27 22783042-5 2012 Over the past 20 years, IFN therapy has improved to more effectively eliminate the virus, progressing from single IFN therapy to combination therapy with ribavirin (RBV) and finally to pegylated IFN (PEG-IFN) therapy. Ribavirin 165-168 interferon alpha 1 Homo sapiens 24-27 22729189-12 2012 CONCLUSION: In patients with HCV genotypes 2 or 3 infection, a higher SVR was observed in patients receiving Peg-IFN plus RBV related to patients treated with biosimilar standard IFN plus RBV. Ribavirin 122-125 interferon alpha 1 Homo sapiens 179-182 22729189-12 2012 CONCLUSION: In patients with HCV genotypes 2 or 3 infection, a higher SVR was observed in patients receiving Peg-IFN plus RBV related to patients treated with biosimilar standard IFN plus RBV. Ribavirin 188-191 interferon alpha 1 Homo sapiens 113-116 22483497-6 2012 The preemptive IFN/RBV protocol initiated treatment promptly after improvement in the patient"s general condition with a low-dose IFN alpha2b and RBV (400 mg/d) followed by a gradual increase in the INFalpha2b dosage. Ribavirin 19-22 interferon alpha 1 Homo sapiens 130-133 22351942-5 2012 Baseline CD16(+)56(-) NK IFN-alphaR expression was associated with IFN-alpha-induced pSTAT1, and both were associated with magnitude of HCV decrease during pegylated IFN-alpha plus ribavirin therapy. Ribavirin 181-190 interferon alpha 1 Homo sapiens 25-34 22357660-9 2012 CONCLUSIONS: Ribavirin augments the anti-HCV effects of IFN-alpha induced by ISGs through enhancing autocrine IFN-beta. Ribavirin 13-22 interferon alpha 1 Homo sapiens 56-65 22483497-6 2012 The preemptive IFN/RBV protocol initiated treatment promptly after improvement in the patient"s general condition with a low-dose IFN alpha2b and RBV (400 mg/d) followed by a gradual increase in the INFalpha2b dosage. Ribavirin 146-149 interferon alpha 1 Homo sapiens 15-18 22300892-3 2012 The aims of the study were to assess safety, tolerability and virological response in patients who were previous PEG-IFN-alpha/ribavirin non-responders. Ribavirin 127-136 interferon alpha 1 Homo sapiens 117-120 22038554-3 2012 This drug has few side effects and reinforces the effect of IFN when administered in combination with peg-IFN and ribavirin. Ribavirin 114-123 interferon alpha 1 Homo sapiens 60-63 22212579-4 2012 However, early clinical studies provide strong evidence for a benefit of RBV in combination with DAAs for both IFN containing and sparing regimens. Ribavirin 73-76 interferon alpha 1 Homo sapiens 111-114 21932410-1 2012 UNLABELLED: Pegylated interferon-alpha2/ribavirin (peg-IFN/RBV) is the standard of care (SOC) for patients with chronic hepatitis C (CHC) infection. Ribavirin 40-49 interferon alpha 1 Homo sapiens 55-58 23258094-4 2012 This retrospective study examined the efficacy of retreatment with PEG-IFNalpha-2a + RBV by evaluating the time to eradication of hepatitis C virus RNA, early virological response (EVR), and SVR. Ribavirin 83-88 interferon alpha 1 Homo sapiens 71-79 21898478-11 2012 CONCLUSION: Gene expression involving innate immunity is strongly associated with IL28B genotype and response to PEG-IFNalpha/RBV. Ribavirin 126-129 interferon alpha 1 Homo sapiens 117-125 21293098-1 2012 OBJECTIVE: Hepatitis C virus (HCV genome) polymorphisms are thought to influence the outcome of pegylated-interferon/ribavirin (PEG-IFN/RBV) therapy. Ribavirin 117-126 interferon alpha 1 Homo sapiens 132-139 21734353-10 2012 CONCLUSION: aa substitution in core/NS5A region and genetic variation near IL28B were important predictors of treatment efficacy to IFN/ribavirin. Ribavirin 136-145 interferon alpha 1 Homo sapiens 132-135 21918436-4 2011 IL28B variations are strongly associated with response to pegylated-IFN plus ribavirin (Peg-IFN/RBV) in patients with chronic infection by HCV genotype 1 or 4. Ribavirin 77-86 interferon alpha 1 Homo sapiens 92-95 22635082-2 2012 CASE PRESENTATION: We present a 38-year-old woman who has been treated with combined pegylated interferon alpha (INF-alpha) and Ribavirin for chronic hepatitis C. Destructive thyrotoxicosis appeared after four months of continuous IFN-alpha therapy and a beta blocker was prescribed. Ribavirin 128-137 interferon alpha 1 Homo sapiens 231-240 22328925-9 2012 These results demonstrate that rs12979860, compared to rs8099917, may be a better predictor of response to the peg-IFN/RBV treatment among HCV/HIV-1 coinfected patients. Ribavirin 119-122 interferon alpha 1 Homo sapiens 115-118 21320556-1 2011 Ribavirin (RBV) is a potential partner of interferon (IFN)-based therapy for patients with chronic hepatitis C. However, to date, its anti-hepatitis C virus (HCV) mechanism remains ambiguous due to the marginal activity of RBV on HCV RNA replication in HuH-7-derived cells, which are currently used as the only cell culture system for robust HCV replication. Ribavirin 0-9 interferon alpha 1 Homo sapiens 42-52 21439960-8 2011 CONCLUSIONS: High-dose pegylated IFN-alpha with standard or high doses of ribavirin induces a potent antiviral response in a substantial number of patients who did not respond to standard therapy. Ribavirin 74-83 interferon alpha 1 Homo sapiens 33-42 21748625-4 2011 About 13 months after the initiation of antiviral therapy, in the form of type 2b peg-IFN with ribavirin, a negative serum hepatitis C virus (HCV)-RNA titer was confirmed. Ribavirin 95-104 interferon alpha 1 Homo sapiens 86-89 21575275-1 2011 BACKGROUND: Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN alpha/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin). Ribavirin 128-137 interferon alpha 1 Homo sapiens 159-168 21575275-2 2011 PegIFN/ribavirin has increased rate of sustained virological response than standard IFN alpha/ribavirin therapy. Ribavirin 7-16 interferon alpha 1 Homo sapiens 84-93 21572662-11 2011 Naranjo causality assessment scale revealed probable association with IFN-alpha and ribavirin. Ribavirin 84-93 interferon alpha 1 Homo sapiens 70-79 21320556-1 2011 Ribavirin (RBV) is a potential partner of interferon (IFN)-based therapy for patients with chronic hepatitis C. However, to date, its anti-hepatitis C virus (HCV) mechanism remains ambiguous due to the marginal activity of RBV on HCV RNA replication in HuH-7-derived cells, which are currently used as the only cell culture system for robust HCV replication. Ribavirin 0-9 interferon alpha 1 Homo sapiens 54-57 21320556-1 2011 Ribavirin (RBV) is a potential partner of interferon (IFN)-based therapy for patients with chronic hepatitis C. However, to date, its anti-hepatitis C virus (HCV) mechanism remains ambiguous due to the marginal activity of RBV on HCV RNA replication in HuH-7-derived cells, which are currently used as the only cell culture system for robust HCV replication. Ribavirin 11-14 interferon alpha 1 Homo sapiens 42-52 21320556-1 2011 Ribavirin (RBV) is a potential partner of interferon (IFN)-based therapy for patients with chronic hepatitis C. However, to date, its anti-hepatitis C virus (HCV) mechanism remains ambiguous due to the marginal activity of RBV on HCV RNA replication in HuH-7-derived cells, which are currently used as the only cell culture system for robust HCV replication. Ribavirin 11-14 interferon alpha 1 Homo sapiens 54-57 21111740-1 2011 Preactivation of this endogenous IFN system is associated with nonresponse to pegylated IFN-alpha (pegIFN-alpha) and ribavirin. Ribavirin 117-126 interferon alpha 1 Homo sapiens 33-36 21159314-8 2011 We conclude that BCL-2 gene polymorphism at codon 43 (127G/A) is a new biological marker to potentially identify responders and non-responders of HCV genotype 4 patients to achieving a sustained virological response to treatment with IFN in combination with ribavirin. Ribavirin 258-267 interferon alpha 1 Homo sapiens 234-237 20667172-5 2011 For this purpose, 17 hepatitis C patients received IFN-alpha treatment with ribavirin. Ribavirin 76-85 interferon alpha 1 Homo sapiens 51-60 21143041-6 2011 The results of these studies suggested that the addition of this specific protease inhibitor to PEG IFN alfa-2a and RBV can significantly improve the results of treatment in patients affected with chronic HCV infection with genotype 1, when compared with the standard treatment, PEG IFN alfa-2a and RBV alone. Ribavirin 116-119 interferon alpha 1 Homo sapiens 283-286 21143041-6 2011 The results of these studies suggested that the addition of this specific protease inhibitor to PEG IFN alfa-2a and RBV can significantly improve the results of treatment in patients affected with chronic HCV infection with genotype 1, when compared with the standard treatment, PEG IFN alfa-2a and RBV alone. Ribavirin 299-302 interferon alpha 1 Homo sapiens 100-103 21143041-10 2011 RBV remains an essential component of treatment with protease inhibitors combined with PEG IFN. Ribavirin 0-3 interferon alpha 1 Homo sapiens 91-94 22155905-7 2011 Decreases in MMP-9 activity were mediated by IFN-alpha, which also attenuated RBV induction of MMP-9 activity and protein expression in THP-1 cells. Ribavirin 78-81 interferon alpha 1 Homo sapiens 45-54 21269387-9 2011 CONCLUSION: Potent combination therapy with PEG-IFN and ribavirin is likely associated with the increase in IFN-related type 1 diabetes. Ribavirin 58-67 interferon alpha 1 Homo sapiens 110-113 20924369-3 2011 Single-nucleotide polymorphisms in the region of the IL28B gene on chromosome 19, coding for the interferon (IFN)-lambda-3 or IL28B gene, are strongly associated with treatment response to pegylated IFN and ribavirin in patients infected with genotype 1 HCV. Ribavirin 207-216 interferon alpha 1 Homo sapiens 109-112 22155905-11 2011 RBV/pegylated IFN-alpha decreased plasma MMP-9 abundance in HIV-HCV patients. Ribavirin 0-3 interferon alpha 1 Homo sapiens 14-23 21734383-3 2011 RESULTS: Single nucleotide polymorphisms near the IL28B gene location which encode for interferon (IFN)-lambda3 have a large effect in determining the likelihood of patients obtaining a cure from pegylated IFN-alpha and ribavirin combination therapy or spontaneous clearance of the HCV. Ribavirin 220-229 interferon alpha 1 Homo sapiens 206-215 20438578-0 2011 Antiviral re-treatment of IFN-ribavirin non-responders for recurrent post-transplantation hepatitis C. BACKGROUND: The aim of the study was to compare the efficacy and tolerability of pegylated interferon (PEG-IFN) plus ribavirin (RIB) and PEG-IFN monotherapy after unsuccessful initial therapy with interferon-alpha2b (IFN) plus RIB after recurrent post-transplantation hepatitis C. METHODS: Twenty-four patients with either no response (n = 10) or relapse (n = 14) after treatment with IFN plus RIB were prospectively randomized in the two treatment arms: 1) PEG-IFN monotherapy at a dosage of 0.8 mug/kg per week (n = 12) and 2) PEG-IFN (0.8 mug/kg per week) plus RIB (800-1200 mg/d) (n = 12). Ribavirin 30-39 interferon alpha 1 Homo sapiens 26-29 22156478-1 2011 Combination therapy of pegylated interferon-alpha with ribavirin (PEG-IFN/RBV) is a standard of care for chronic hepatitis C (CHC). Ribavirin 55-64 interferon alpha 1 Homo sapiens 70-73 22879793-1 2011 Combined pegylated interferon (PEG-IFN)+ribavirin (RBV) therapy has been used as a primary treatment for chronic hepatitis C. However, IFN-induced autoimmune disease, including type 1 diabetes mellitus, has been highlighted as one of the problems with this therapy. Ribavirin 40-49 interferon alpha 1 Homo sapiens 135-138 22879793-1 2011 Combined pegylated interferon (PEG-IFN)+ribavirin (RBV) therapy has been used as a primary treatment for chronic hepatitis C. However, IFN-induced autoimmune disease, including type 1 diabetes mellitus, has been highlighted as one of the problems with this therapy. Ribavirin 51-54 interferon alpha 1 Homo sapiens 135-138 20822376-1 2011 OBJECTIVE: Several treatment strategies for patients with chronic hepatitis C have been compared mainly in terms of their efficacy, and it has been found that pegylated interferon (IFN) plus ribavirin has become the standard therapy, but aged patients may not tolerate ribavirin and the cost-effectiveness of treatment should also be further considered. Ribavirin 269-278 interferon alpha 1 Homo sapiens 181-184 21254160-1 2011 UNLABELLED: The combination of pegylated interferon (PEG-IFN) and ribavirin is the standard treatment for chronic hepatitis C. Our recent clinical study suggests that ribavirin augments the induction of interferon-stimulated genes (ISGs) in patients treated for hepatitis C virus (HCV) infection. Ribavirin 167-176 interferon alpha 1 Homo sapiens 57-60 21576995-4 2011 In contrast to IL-17, IFN-gamma showed significant reduction after 12 weeks of treatment with pegylated IFN plus ribavirin. Ribavirin 113-122 interferon alpha 1 Homo sapiens 22-25 22114715-0 2011 Ribavirin enhances IFN-alpha signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. Ribavirin 0-9 interferon alpha 1 Homo sapiens 19-28 22114715-1 2011 The nucleoside analogue Ribavirin significantly increases patient response to IFN-alpha treatment of HCV, by directly inhibiting viral replication. Ribavirin 24-33 interferon alpha 1 Homo sapiens 78-87 22114715-2 2011 Recent studies indicate that Ribavirin also regulates immunity and we propose that Ribavirin enhances specific interferon sensitive gene (ISG) expression by amplifying the IFN-alpha-JAK/STAT pathway. Ribavirin 29-38 interferon alpha 1 Homo sapiens 172-181 22114715-2 2011 Recent studies indicate that Ribavirin also regulates immunity and we propose that Ribavirin enhances specific interferon sensitive gene (ISG) expression by amplifying the IFN-alpha-JAK/STAT pathway. Ribavirin 83-92 interferon alpha 1 Homo sapiens 172-181 22114715-3 2011 We found that IFN-alpha-induced STAT1 and STAT3 phosphorylation was increased in hepatocytes co-treated with Ribavirin and IFN-alpha, compared to IFN-alpha alone. Ribavirin 109-118 interferon alpha 1 Homo sapiens 14-23 22114715-4 2011 Ribavirin specifically enhanced IFN-alpha induced mRNA and protein of the anti-viral mediator MxA, which co-localised with HCV core protein. Ribavirin 0-9 interferon alpha 1 Homo sapiens 32-41 22114715-5 2011 These novel findings indicate for the first time that Ribavirin, in addition to its viral incorporation, also enhances IFN-alpha-JAK/STAT signalling, leading to a novel MxA-mediated immuno-modulatory mechanism that may enhance IFN-alpha anti-viral activity against HCV. Ribavirin 54-63 interferon alpha 1 Homo sapiens 119-128 22114715-5 2011 These novel findings indicate for the first time that Ribavirin, in addition to its viral incorporation, also enhances IFN-alpha-JAK/STAT signalling, leading to a novel MxA-mediated immuno-modulatory mechanism that may enhance IFN-alpha anti-viral activity against HCV. Ribavirin 54-63 interferon alpha 1 Homo sapiens 227-236 21603632-0 2011 Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. BACKGROUND: Despite being expensive, the standard combination of pegylated interferon (Peg-IFN)-alpha and ribavirin used to treat chronic hepatitis C (CH) results in a moderate clearance rate and a plethora of side effects. Ribavirin 82-91 interferon alpha 1 Homo sapiens 17-20 21603632-0 2011 Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. BACKGROUND: Despite being expensive, the standard combination of pegylated interferon (Peg-IFN)-alpha and ribavirin used to treat chronic hepatitis C (CH) results in a moderate clearance rate and a plethora of side effects. Ribavirin 230-239 interferon alpha 1 Homo sapiens 17-20 21254160-10 2011 CONCLUSION: Our study suggests that ribavirin, acting by way of a novel innate mechanism, potentiates the anti-HCV effect of IFN. Ribavirin 36-45 interferon alpha 1 Homo sapiens 125-128 20646277-15 2010 CONCLUSIONS: PEG-IFN alpha-2b plus weight-based ribavirin is effective in re-treating previous interferon-alpha plus RBV failure; 22.2% of the patients with genotype 1 HCV and 40% of patients with genotype 3 HCV achieved SVR. Ribavirin 117-120 interferon alpha 1 Homo sapiens 17-20 21076689-6 2010 For the first time, the case reports below highlight the same immunological adverse event secondary to PEG IFN-alpha 2a/ribavirin combination therapy and explain, in part, the complex interaction between host immune response and viral genotype. Ribavirin 120-129 interferon alpha 1 Homo sapiens 107-116 20887330-1 2010 AIM: Recent human genome-wide association studies (GWAS) revealed a strong association between IL28B gene variation and the pegylated interferon-alpha with ribavirin (PEG-IFN-alpha/RBV) treatment response in chronic hepatitis C patients. Ribavirin 158-167 interferon alpha 1 Homo sapiens 173-182 20627191-7 2010 It is suggested that the interferon (IFN)-alpha/ribavirin therapy starting 2 months may be an effective option and now is undertaken. Ribavirin 48-57 interferon alpha 1 Homo sapiens 25-47 20006404-0 2010 Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients. Ribavirin 80-89 interferon alpha 1 Homo sapiens 70-73 20028490-12 2010 In LDLT for HCV, pre-emptive IFN-RBV-based treatment with the application of no-stopping approach is feasible and effective. Ribavirin 33-36 interferon alpha 1 Homo sapiens 29-32 20546329-4 2010 Recent genome-wide association studies (GWAS) of the human whole genome revealed several single nucleotide polymorphism sites (SNP) strongly associated with the response to pegylated IFN-alpha (PEG-IFN) plus ribavirin (RBV) treatment in chronic hepatitis C patients. Ribavirin 219-222 interferon alpha 1 Homo sapiens 183-192 20546329-4 2010 Recent genome-wide association studies (GWAS) of the human whole genome revealed several single nucleotide polymorphism sites (SNP) strongly associated with the response to pegylated IFN-alpha (PEG-IFN) plus ribavirin (RBV) treatment in chronic hepatitis C patients. Ribavirin 219-222 interferon alpha 1 Homo sapiens 183-186 20070395-0 2010 Advantage of IFN-beta/alpha2b same-day administration for ribavirin-intolerant patients with chronic hepatitis C. AIM: Although interferon (IFN)/ribavirin is the mainstream combination treatment for chronic hepatitis C in patients with a high viral load, ribavirin is problematic for women of childbearing age and patients with anemia. Ribavirin 58-67 interferon alpha 1 Homo sapiens 13-16 20070395-4 2010 among 138 patients who underwent IFN treatment after ribavirin release. Ribavirin 53-62 interferon alpha 1 Homo sapiens 33-36 20101190-1 2010 BACKGROUND: This study aimed to assess the relationship between interferon (IFN)-related adverse effects and Hepatitis C virus (HCV) virologic response in HIV/HCV-coinfected individuals treated with pegylated interferon and ribavirin. Ribavirin 224-233 interferon alpha 1 Homo sapiens 76-79 19690915-1 2010 BACKGROUND: This study aimed to evaluate whether laparoscopic splenectomy (Lap-Sp) contributes to the completion and curability of combined peginterferon and ribavirin (peg-IFN + RIB) therapy for cirrhotic patients with pancytopenia due to hypersplenism. Ribavirin 158-167 interferon alpha 1 Homo sapiens 173-176 20163278-1 2010 IMPORTANCE OF THE FIELD: Ribavirin is a broad spectrum antiviral agent that is used with pegylated IFN (Peg-IFN) for HCV treatment. Ribavirin 25-34 interferon alpha 1 Homo sapiens 99-111 20006404-0 2010 Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients. Ribavirin 91-94 interferon alpha 1 Homo sapiens 70-73 26192611-7 2009 The patient had received IFN therapy twice previously (IFN-alpha 2a and IFN-alpha 2b with ribavirin therapy); however, no adverse side effects were observed. Ribavirin 90-99 interferon alpha 1 Homo sapiens 25-28 20068341-1 2010 We investigated whether sustained virological response (SVR) and non-SVR by chronic hepatitis C patients to pegylated interferon plus ribavirin (PEG-IFN/RBV) combination therapy are distinguishable by viral factors such as the IFN/RBV resistance-determining region (IRRDR) and by on-treatment factors through new indices such as the rebound index (RI). Ribavirin 134-143 interferon alpha 1 Homo sapiens 149-156 21152181-2 2010 Treatment with IFN-alpha is more efficient when it complemented by the antiviral ribavirin and the IFN-alpha is conjugated with polyethylene glycol to form peginterferon. Ribavirin 81-90 interferon alpha 1 Homo sapiens 15-24 20625493-2 2010 Currently, HCV-infected patients could undergo antiviral therapy by giving pegylated IFN-alpha with ribavirin. Ribavirin 100-109 interferon alpha 1 Homo sapiens 85-94 19619545-0 2009 Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities. Ribavirin 0-9 interferon alpha 1 Homo sapiens 19-29 19619545-1 2009 Cellular mechanisms involving the enhancement of interferon (IFN) signaling by ribavirin remain poorly understood. Ribavirin 79-88 interferon alpha 1 Homo sapiens 49-59 19619545-1 2009 Cellular mechanisms involving the enhancement of interferon (IFN) signaling by ribavirin remain poorly understood. Ribavirin 79-88 interferon alpha 1 Homo sapiens 61-64 19619545-5 2009 Furthermore, ribavirin-induced activation of mTOR and p53 enhances IFN-dependent signaling for the IFN-alpha/ribavirin combined treatment. Ribavirin 13-22 interferon alpha 1 Homo sapiens 67-70 19619545-5 2009 Furthermore, ribavirin-induced activation of mTOR and p53 enhances IFN-dependent signaling for the IFN-alpha/ribavirin combined treatment. Ribavirin 13-22 interferon alpha 1 Homo sapiens 99-108 19619545-5 2009 Furthermore, ribavirin-induced activation of mTOR and p53 enhances IFN-dependent signaling for the IFN-alpha/ribavirin combined treatment. Ribavirin 109-118 interferon alpha 1 Homo sapiens 67-70 19619545-5 2009 Furthermore, ribavirin-induced activation of mTOR and p53 enhances IFN-dependent signaling for the IFN-alpha/ribavirin combined treatment. Ribavirin 109-118 interferon alpha 1 Homo sapiens 99-108 19262360-8 2009 These preliminary experiences evidenced that combination treatment of PEG-IFN-alpha2b with ribavirin shows encouraging results and was well tolerated in children and adolescents with chronic hepatitis C. Ribavirin 91-100 interferon alpha 1 Homo sapiens 74-77 19345260-1 2009 The current FDA-approved treatment for HCV (pegylated interferon-alpha (IFNalpha) with ribavirin) is effective in only about 50% of patients. Ribavirin 87-96 interferon alpha 1 Homo sapiens 72-80 19753589-0 2009 Pleural effusion associated with pegylated interferon alpha and ribavirin treatment for chronic hepatitis C. Lung toxicity related to interferon (IFN) alpha typically takes a form of interstitial pneumonitis, granulomatous inflammation, or organizing pneumonia. Ribavirin 64-73 interferon alpha 1 Homo sapiens 134-156 19428584-4 2009 The system has been validated using interferon (IFN), which is still the only consensual antiviral agent against HCV infection, associated with ribavirin. Ribavirin 144-153 interferon alpha 1 Homo sapiens 36-52 19482597-2 2009 The addition of ribavirin to IFN therapy has increased the response rate dramatically. Ribavirin 16-25 interferon alpha 1 Homo sapiens 29-32 19200137-1 2009 Interferon (IFN)-based combination therapy with ribavirin has become the gold standard for the treatment of chronic hepatitis C virus infection. Ribavirin 48-57 interferon alpha 1 Homo sapiens 12-15 19033352-3 2009 As there is no previous data to fully characterize the entity of IFN-related thyroiditis, the aim of this study is to document in detail its evolution in a cohort of hepatitis C patients treated with pegylated IFN-alpha2b and Ribavirin (RBV). Ribavirin 226-235 interferon alpha 1 Homo sapiens 65-68 19578615-1 2009 CONTEXT: It has been suggested that coinfected patients HCV/HIV must be treated with pegylated interferon associated to ribavirin (PEG+RBV), because of better taxes of sustained virological response when compared to those treated with conventional interferon associated to ribavirin (IFN+RBV). Ribavirin 120-129 interferon alpha 1 Homo sapiens 248-291 19578615-1 2009 CONTEXT: It has been suggested that coinfected patients HCV/HIV must be treated with pegylated interferon associated to ribavirin (PEG+RBV), because of better taxes of sustained virological response when compared to those treated with conventional interferon associated to ribavirin (IFN+RBV). Ribavirin 135-138 interferon alpha 1 Homo sapiens 248-291 19033352-3 2009 As there is no previous data to fully characterize the entity of IFN-related thyroiditis, the aim of this study is to document in detail its evolution in a cohort of hepatitis C patients treated with pegylated IFN-alpha2b and Ribavirin (RBV). Ribavirin 237-240 interferon alpha 1 Homo sapiens 65-68 19028630-6 2008 Our case report provides new significant insight on the histopathological changes occurring in bone marrow of HCV-infected cirrhotic patients during peg-IFN alpha-2a plus RBV treatment, providing also additional information on potential bone marrow toxicity in the course of IFN-based treatments. Ribavirin 171-174 interferon alpha 1 Homo sapiens 275-278 19249526-3 2009 We have reported herein the efficacy of divided administration of interferon (IFN) beta plus cyclosporine for chronic hepatitis C patients who failed pegylated (Peg)-IFN or IFN combined ribavirin treatment. Ribavirin 186-195 interferon alpha 1 Homo sapiens 78-81 19061675-1 2008 OBJECTIVE: This study was designed to determine the effect of 12-week pegylated IFNalpha plus ribavirin (peg-IFNalpha/RBV) treatment on cognitive performance in chronic hepatitis C (CHC) patients. Ribavirin 94-103 interferon alpha 1 Homo sapiens 109-117 19061675-8 2008 CONCLUSION: The findings suggest that peg-IFNalpha/RBV therapy of CHC patients is related to cognitive performance decline and is a result of IFNalpha-induced neurotransmission abnormalities in the limbic system, dorsolateral prefrontal cortex and anterior cingulate cortex. Ribavirin 51-54 interferon alpha 1 Homo sapiens 42-50 19061675-8 2008 CONCLUSION: The findings suggest that peg-IFNalpha/RBV therapy of CHC patients is related to cognitive performance decline and is a result of IFNalpha-induced neurotransmission abnormalities in the limbic system, dorsolateral prefrontal cortex and anterior cingulate cortex. Ribavirin 51-54 interferon alpha 1 Homo sapiens 142-150 19687584-0 2009 Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN alone, induced type 1 diabetes in a patient with chronic hepatitis C. Interferon (IFN) therapies, including IFN, peginterferon (PEG-IFN) and ribavirin (RBV) plus PEG-IFN combination, are widely used for patients with chronic hepatitis C. We encountered a patient with chronic hepatitis C in whom previous IFN or PEG-IFN alone had not induced type 1 diabetes (T1D), while the addition of RBV to PEG-IFN did induce T1D. Ribavirin 29-38 interferon alpha 1 Homo sapiens 165-175 19117241-3 2009 Depending on the weight-based ribavirin dose, patients with >105 kg reach a maximum of 13.2 mg/kg body-weight ribavirin in the peg-IFN alfa-2b regimen as opposed to only 11.3 mg/kg in the peg-IFN alfa-2a regimen. Ribavirin 113-122 interferon alpha 1 Homo sapiens 134-137 19441669-1 2008 UNLABELLED: Chronic hepatitis C (CHC) patients treated with peg-interferon alpha and ribavirin (peg-IFNalpha/RBV) complain of irritability, attention and memory disturbances which may indicate cognitive impairment associated with treatment. Ribavirin 85-94 interferon alpha 1 Homo sapiens 100-108 19441669-1 2008 UNLABELLED: Chronic hepatitis C (CHC) patients treated with peg-interferon alpha and ribavirin (peg-IFNalpha/RBV) complain of irritability, attention and memory disturbances which may indicate cognitive impairment associated with treatment. Ribavirin 109-112 interferon alpha 1 Homo sapiens 100-108 19441669-10 2008 CONCLUSIONS: The findings suggest that peg-IFNalpha/RBV therapy of CHC patients is connected with the deterioration in cognitive functioning including attention, auditory verbal memory and visuo-spatial skills. Ribavirin 52-55 interferon alpha 1 Homo sapiens 43-51 17939042-7 2008 CONCLUSIONS: Combined treatment with L: -carnitine, ribavirin and IFN alpha resulted in greater antihyperlipidaemic effects and than with ribavirin and IFN alpha alone. Ribavirin 52-61 interferon alpha 1 Homo sapiens 152-161 18248380-0 2008 Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. BACKGROUND AND AIM: It has been reported that immunological factors, such as the T-helper cell (Th)1/Th2 ratio, play a part in the mechanisms for the antihepatitis C virus (HCV) effect of the interferon (IFN) alpha-2b plus ribavirin combination therapy. Ribavirin 84-93 interferon alpha 1 Homo sapiens 345-361 18248380-8 2008 CONCLUSIONS: The significant changes in the Th2 level correlated with the therapeutic effect during the IFN alpha-2b plus ribavirin combination therapy. Ribavirin 122-131 interferon alpha 1 Homo sapiens 104-107 18551610-1 2008 The efficacy of interferon (IFN) monotherapy for non-responders to pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy is still unclear. Ribavirin 103-112 interferon alpha 1 Homo sapiens 28-31 18551610-9 2008 The results suggest that low-dose intermittent IFN monotherapy is an efficacious therapeutic regimen for patients unsuitable for PEG-IFN plus RBV, including non-responders, because it can lead to ALT normalization and thus a reduced risk of hepatocarcinogenesis. Ribavirin 142-145 interferon alpha 1 Homo sapiens 47-50 18702333-1 2008 UNLABELLED: The aim of the study was to describe describe the frequency of depressive symptoms and episodes accompanying peg-interferon alpha and ribavirin (peg-IFN-alpha/RBV) treatment of chronic hepatitis C patients (CHC). Ribavirin 146-155 interferon alpha 1 Homo sapiens 161-170 18258414-4 2008 Compared to control subjects, patients treated with IFN-alpha/ribavirin exhibited significant decreases in motor speed as measured in the simple and five-choice movement segments of the CANTAB reaction time task and slower response times in the rapid visual information processing task, a task of sustained attention. Ribavirin 62-71 interferon alpha 1 Homo sapiens 52-61 18636675-8 2008 After LS, since her platelet count immediately increased to 225,000/microL 14 d after operation, IFN therapy was restarted and we could convert the combination therapy of IFN and ribavirin, resulting in no detectable viral marker. Ribavirin 179-188 interferon alpha 1 Homo sapiens 97-100 18646554-7 2008 The inhibitory effect of ribavirin dominated IFN-alpha action and was responsible for the decrease in the mRNA levels of IFN-gamma and the receptor of IFN-gamma. Ribavirin 25-34 interferon alpha 1 Homo sapiens 45-54 17939042-7 2008 CONCLUSIONS: Combined treatment with L: -carnitine, ribavirin and IFN alpha resulted in greater antihyperlipidaemic effects and than with ribavirin and IFN alpha alone. Ribavirin 138-147 interferon alpha 1 Homo sapiens 66-75 18672537-2 2008 A single test dose of IFN was useful to identify non-responders to IFN-alpha2b/ribavirin (RBV) or likely non-responders to pegylated (PEG)-IFN-alpha2a/RBV therapy in genotype 1 patients. Ribavirin 79-88 interferon alpha 1 Homo sapiens 22-25 18215704-6 2008 INTERVENTION: IFN-based treatment, including PEG-IFN with and without ribavirin. Ribavirin 70-79 interferon alpha 1 Homo sapiens 14-17 18672537-2 2008 A single test dose of IFN was useful to identify non-responders to IFN-alpha2b/ribavirin (RBV) or likely non-responders to pegylated (PEG)-IFN-alpha2a/RBV therapy in genotype 1 patients. Ribavirin 90-93 interferon alpha 1 Homo sapiens 22-25 18672537-2 2008 A single test dose of IFN was useful to identify non-responders to IFN-alpha2b/ribavirin (RBV) or likely non-responders to pegylated (PEG)-IFN-alpha2a/RBV therapy in genotype 1 patients. Ribavirin 151-154 interferon alpha 1 Homo sapiens 22-25 18672537-10 2008 A 24 h log10 change after 10 MU IFN-alpha2b is an excellent predictor of SVR on PEG-IFNalpha2a/RBV combination therapy. Ribavirin 95-98 interferon alpha 1 Homo sapiens 32-35 18652518-3 2008 METHODS: Using single nucleotide polymorphisms (SNPs) and viral genotype, we applied the support vector machine (SVM) algorithm to build a tool to predict responsiveness to IFNalpha-ribavirin combination therapy. Ribavirin 182-191 interferon alpha 1 Homo sapiens 173-181 17675168-2 2007 The current treatment with IFN-alpha given alone or in combination with ribavirin is ineffective in eliminating the virus in a large proportion of individuals with chronic hepatitis C. Recent data suggest that HCV blocks IFN-alpha signalling, an effect that facilitates viral persistence. Ribavirin 72-81 interferon alpha 1 Homo sapiens 221-230 17852932-6 2008 To conclude, we found that utilizing a low initial daily RBV dose, later increased due to tolerance in combination with peg-IFN alpha-2a 180 microg weekly, was successful. Ribavirin 57-60 interferon alpha 1 Homo sapiens 124-127 17968840-12 2007 CONCLUSIONS: In patients with symptomatic DILI, treatment with IFN-ribavirin (RBV) led to decreases in aminotransferase levels, which enabled the reinitiation of ART. Ribavirin 67-76 interferon alpha 1 Homo sapiens 63-66 17968840-12 2007 CONCLUSIONS: In patients with symptomatic DILI, treatment with IFN-ribavirin (RBV) led to decreases in aminotransferase levels, which enabled the reinitiation of ART. Ribavirin 78-81 interferon alpha 1 Homo sapiens 63-66 17629590-9 2007 CONCLUSIONS: In conclusion, PEG-IFN-alpha2b and RBV combined with 50 mg MMPD q12h was well tolerated and induced virological response with undetectable HCV RNA in IFN-alpha and RBV nonresponders. Ribavirin 48-51 interferon alpha 1 Homo sapiens 32-35 17958644-3 2007 Better results have recently been reported with pegylated IFN both in IFN-naive and in previous nonresponders to standard IFN, suggesting the use of pegylated IFN as a first-line therapy in chronic hepatitis D. Nucleoside analogues that inhibit hepatitis B virus (HBV) are ineffective against HDV and combination therapy with lamivudine or ribavirin has not shown significant advantages over monotherapy with either standard or pegylated IFN. Ribavirin 340-349 interferon alpha 1 Homo sapiens 58-61 17929300-11 2007 The patients pretreated with ribavirin had heightened induction of IFN-related genes and down-regulation of genes involved in IFN inhibition and hepatic stellate cell activation. Ribavirin 29-38 interferon alpha 1 Homo sapiens 67-70 17929300-11 2007 The patients pretreated with ribavirin had heightened induction of IFN-related genes and down-regulation of genes involved in IFN inhibition and hepatic stellate cell activation. Ribavirin 29-38 interferon alpha 1 Homo sapiens 126-129 17914965-7 2007 Multiple regression analysis showed that TIS was the only independent variable associated with resistance to IFN/ribavirin (P = 0.0277). Ribavirin 113-122 interferon alpha 1 Homo sapiens 109-112 17724740-0 2007 Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. PURPOSE: Administration of pegylated interferon-alpha (IFN-alpha) and ribavirin in adults with chronic hepatitis C (CHC) is a recommended therapeutic standard. Ribavirin 67-76 interferon alpha 1 Homo sapiens 170-179 17629590-9 2007 CONCLUSIONS: In conclusion, PEG-IFN-alpha2b and RBV combined with 50 mg MMPD q12h was well tolerated and induced virological response with undetectable HCV RNA in IFN-alpha and RBV nonresponders. Ribavirin 48-51 interferon alpha 1 Homo sapiens 163-166 17660602-0 2007 IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C. The aim of the study was to observe the frequency of neutropenia during Pegylated Interferon/Ribavirin therapy in patient with chronic hepatitis C; to compare the efficacy of two strategies of management of neutropenia--with Interferon dose modification and with Neupogen administration; to compare the effectiveness rate of sustained viral response (SVR) in patients with Pegylated Interferon dose modification and in patients treated by using granulocyte colony-stimulating factor G-CSF-filgrastim. Ribavirin 194-203 interferon alpha 1 Homo sapiens 0-3 17897248-5 2007 There are only limited data about pegylated IFN alone or in association with ribavirin for hepatitis C in dialysis population. Ribavirin 77-86 interferon alpha 1 Homo sapiens 44-47 17597457-9 2007 The effects that treatment with ribavirin plus IFN- alpha had on PKR activity were greater than those observed for treatment with either ribavirin alone or IFN- alpha alone. Ribavirin 32-41 interferon alpha 1 Homo sapiens 156-166 17663735-8 2007 RESULTS: Among human immunodeficiency virus (HIV) negative patients (n = 235), SVR was 29% (29/101) for IFN monotherapy, 44% (32/72) for IFN with ribavirin, and 63% (39/62) for pegylated IFN (PegIFN) with ribavirin. Ribavirin 146-155 interferon alpha 1 Homo sapiens 137-140 17663735-8 2007 RESULTS: Among human immunodeficiency virus (HIV) negative patients (n = 235), SVR was 29% (29/101) for IFN monotherapy, 44% (32/72) for IFN with ribavirin, and 63% (39/62) for pegylated IFN (PegIFN) with ribavirin. Ribavirin 146-155 interferon alpha 1 Homo sapiens 137-140 17596864-9 2007 Finally, the enhanced third phase in patients treated with IFN-alpha in combination with RBV versus patients treated with IFN-alpha alone can be explained by a mutagenic effect of RBV against HCV. Ribavirin 180-183 interferon alpha 1 Homo sapiens 59-68 17596864-9 2007 Finally, the enhanced third phase in patients treated with IFN-alpha in combination with RBV versus patients treated with IFN-alpha alone can be explained by a mutagenic effect of RBV against HCV. Ribavirin 180-183 interferon alpha 1 Homo sapiens 122-131 17663735-10 2007 SVR increased with genotype 2 and 3 [OR 11.0, 95% CI: 5.8-20.5], and combination therapy (IFN and ribavirin OR 3.7, 95% CI: 1.7-8.4), PegIFN and ribavirin (OR 4.2, 95% CI: 1.8-9.5). Ribavirin 145-154 interferon alpha 1 Homo sapiens 90-93 17539990-11 2007 CONCLUSION: Low dose long-term interferon monotherapy to prevent carcinogenesis of HCC was considered useful in aged patients for whom peg-interferon and ribavirin combination therapy is difficult. Ribavirin 154-163 interferon alpha 1 Homo sapiens 31-41 17589934-0 2007 Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. We report a panel of severe inflammatory and vascular intraocular disorders occurring during interferon-alpha (IFN-alpha) treatment in eight hepatitis C virus (HCV)-infected patients. Ribavirin 43-52 interferon alpha 1 Homo sapiens 216-225 17441804-0 2007 Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C. AIMS: We previously reported the potential effect of combination therapy of an initial high-dose interferon (IFN) and amantadine on the eradication of HCV-RNA in patients with chronic hepatitis C. The additive effects of amantadine on interferon and ribavirin combination therapy remain controversial. Ribavirin 52-61 interferon alpha 1 Homo sapiens 203-229 17441804-0 2007 Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C. AIMS: We previously reported the potential effect of combination therapy of an initial high-dose interferon (IFN) and amantadine on the eradication of HCV-RNA in patients with chronic hepatitis C. The additive effects of amantadine on interferon and ribavirin combination therapy remain controversial. Ribavirin 52-61 interferon alpha 1 Homo sapiens 213-223 17441804-0 2007 Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C. AIMS: We previously reported the potential effect of combination therapy of an initial high-dose interferon (IFN) and amantadine on the eradication of HCV-RNA in patients with chronic hepatitis C. The additive effects of amantadine on interferon and ribavirin combination therapy remain controversial. Ribavirin 366-375 interferon alpha 1 Homo sapiens 36-46 17441804-0 2007 Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C. AIMS: We previously reported the potential effect of combination therapy of an initial high-dose interferon (IFN) and amantadine on the eradication of HCV-RNA in patients with chronic hepatitis C. The additive effects of amantadine on interferon and ribavirin combination therapy remain controversial. Ribavirin 366-375 interferon alpha 1 Homo sapiens 203-229 17441804-0 2007 Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C. AIMS: We previously reported the potential effect of combination therapy of an initial high-dose interferon (IFN) and amantadine on the eradication of HCV-RNA in patients with chronic hepatitis C. The additive effects of amantadine on interferon and ribavirin combination therapy remain controversial. Ribavirin 366-375 interferon alpha 1 Homo sapiens 213-223 17441804-7 2007 CONCLUSION: Triple therapy with an initial high dose of IFN with ribavirin and amantadine may be effective, especially for chronic hepatitis C IFN-retreatment patients with a high viral load of genotype 1b. Ribavirin 65-74 interferon alpha 1 Homo sapiens 56-59 17441804-7 2007 CONCLUSION: Triple therapy with an initial high dose of IFN with ribavirin and amantadine may be effective, especially for chronic hepatitis C IFN-retreatment patients with a high viral load of genotype 1b. Ribavirin 65-74 interferon alpha 1 Homo sapiens 143-146 17376035-1 2007 BACKGROUND: Interferon (IFN) has been well documented to cause thyroid dysfunction, especially in high risk patients and when combined with ribavirin (RBV). Ribavirin 140-149 interferon alpha 1 Homo sapiens 12-28 17444850-8 2007 CONCLUSION: In Japanese patients, peg-IFNalpha-2a plus ribavirin provided significant improvement in SVR rates compared with peg-IFNalpha-2a alone in treatment-naive patients, and was effective as re-treatment for non-responders or relapsers to previous treatment with interferon monotherapy. Ribavirin 55-64 interferon alpha 1 Homo sapiens 129-137 17376035-1 2007 BACKGROUND: Interferon (IFN) has been well documented to cause thyroid dysfunction, especially in high risk patients and when combined with ribavirin (RBV). Ribavirin 151-154 interferon alpha 1 Homo sapiens 12-28 17713164-11 2007 Furthermore, ribavirin treatment modified the efficacy of interferon (IFN) treatment. Ribavirin 13-22 interferon alpha 1 Homo sapiens 70-73 17173661-1 2007 We conducted a study to evaluate the efficacy of pegylated interferon/ribavirin in patients who did not respond to previous posttransplant recurrent HCV treatment with IFN/ribavirin combination. Ribavirin 70-79 interferon alpha 1 Homo sapiens 168-171 17713164-12 2007 The IFN half-inhibition concentration (IC50) was significantly lower for viruses obtained after 1 month"s exposure to 50 microM ribavirin than for viruses cultured in the absence of ribavirin. Ribavirin 128-137 interferon alpha 1 Homo sapiens 4-7 17713164-12 2007 The IFN half-inhibition concentration (IC50) was significantly lower for viruses obtained after 1 month"s exposure to 50 microM ribavirin than for viruses cultured in the absence of ribavirin. Ribavirin 182-191 interferon alpha 1 Homo sapiens 4-7 17477035-0 2007 Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Pulmonary toxicity is a rare but potentially fatal side effect occurring during interferon (IFN) alpha treatment for chronic hepatitis C. We present a 47-year-old woman who had chronic hepatitis C and was treated with pegylated IFN alpha-2b in combination with ribavirin, with a good virological response by week 10 of therapy. Ribavirin 90-99 interferon alpha 1 Homo sapiens 217-220 17477035-0 2007 Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Pulmonary toxicity is a rare but potentially fatal side effect occurring during interferon (IFN) alpha treatment for chronic hepatitis C. We present a 47-year-old woman who had chronic hepatitis C and was treated with pegylated IFN alpha-2b in combination with ribavirin, with a good virological response by week 10 of therapy. Ribavirin 90-99 interferon alpha 1 Homo sapiens 353-356 17477035-5 2007 Based on a MEDLINE search up to 2004, we believe that this is the first reported case of a patient recovering from interstitial pneumonitis associated with pegylated IFN alpha-2b for chronic hepatitis C. Physicians should keep in mind the possibility of this complication when treating chronic hepatitis C patients with pegylated IFN alpha-2b and ribavirin combinational therapy. Ribavirin 347-356 interferon alpha 1 Homo sapiens 166-169 17477035-5 2007 Based on a MEDLINE search up to 2004, we believe that this is the first reported case of a patient recovering from interstitial pneumonitis associated with pegylated IFN alpha-2b for chronic hepatitis C. Physicians should keep in mind the possibility of this complication when treating chronic hepatitis C patients with pegylated IFN alpha-2b and ribavirin combinational therapy. Ribavirin 347-356 interferon alpha 1 Homo sapiens 330-333 17064957-0 2007 Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. Ribavirin 44-53 interferon alpha 1 Homo sapiens 27-30 17133546-6 2007 Multivariate analysis revealed that factors associated with SVR were IFN dose and the number of amino acid substitutions in ISDR but not with subtypes J and W. The correlation between the number of substitutions in ISDR and responses to IFN-ribavirin combination therapy was restricted to patients with J-type HCV 1b. Ribavirin 241-250 interferon alpha 1 Homo sapiens 69-72 17133546-6 2007 Multivariate analysis revealed that factors associated with SVR were IFN dose and the number of amino acid substitutions in ISDR but not with subtypes J and W. The correlation between the number of substitutions in ISDR and responses to IFN-ribavirin combination therapy was restricted to patients with J-type HCV 1b. Ribavirin 241-250 interferon alpha 1 Homo sapiens 237-240 17133546-7 2007 The ISDR is a useful predictive marker for response to IFN-ribavirin combination therapy in J-type HCV. Ribavirin 59-68 interferon alpha 1 Homo sapiens 55-58 17075881-7 2006 Compared with patients treated with IFN alfa-2b plus ribavirin, those receiving PEG-IFN alfa-2b plus ribavirin had a higher sustained clinical (67.5% versus 56.3%), virologic (62.5% versus 53.1%), and immunologic (57.5% versus 31.3%) response, regardless of HCV genotype and viral load. Ribavirin 101-110 interferon alpha 1 Homo sapiens 84-87 18087178-4 2007 Both IFN monotherapy and IFN-ribavirin combination therapy were shown to reduce significantly the complications of liver disease, in terms of development of cirrhosis, HCC and liver-related mortality. Ribavirin 29-38 interferon alpha 1 Homo sapiens 25-28 17702435-5 2007 In the work the data of efficacy of retherapy with PEG IFN alfa-2a+RBV administered during 72 weeks were present. Ribavirin 67-70 interferon alpha 1 Homo sapiens 55-58 17702435-6 2007 Retreatment with PEG IFN alpha-2a and RBV in patients who fail to achieve SVR in the treatment with PEG IFN alpha-2b+RBV revealed high early viral response, in patients with advanced liver histology too. Ribavirin 38-41 interferon alpha 1 Homo sapiens 104-107 17702435-6 2007 Retreatment with PEG IFN alpha-2a and RBV in patients who fail to achieve SVR in the treatment with PEG IFN alpha-2b+RBV revealed high early viral response, in patients with advanced liver histology too. Ribavirin 117-120 interferon alpha 1 Homo sapiens 21-24 17702435-6 2007 Retreatment with PEG IFN alpha-2a and RBV in patients who fail to achieve SVR in the treatment with PEG IFN alpha-2b+RBV revealed high early viral response, in patients with advanced liver histology too. Ribavirin 117-120 interferon alpha 1 Homo sapiens 104-107 17032416-1 2006 Ribavirin, an antiviral agent, potentiates IFN activity when added to it. Ribavirin 0-9 interferon alpha 1 Homo sapiens 43-46 16919076-9 2006 Re-treatment with IFN and ribavirin of those who failed to respond to previous IFN monotherapy was successful in 33%. Ribavirin 26-35 interferon alpha 1 Homo sapiens 79-82 16950651-0 2006 First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C. The aim of the present study was to assess parameters in early phase HCV dynamics for predicting the outcome of interferon (IFN)/ribavirin combination therapy in patients with chronic hepatitis C (CH-C). Ribavirin 87-96 interferon alpha 1 Homo sapiens 267-283 16950651-8 2006 These results demonstrate that parameters of HCV kinetics 24h after the start of therapy are useful for the early prediction of outcome in response to IFN alpha-2b/ribavirin combination therapy. Ribavirin 164-173 interferon alpha 1 Homo sapiens 151-154 16958821-0 2006 2"-,5"-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. OBJECTIVE: Although all the mechanisms of elimination of hepatitis C virus (HCV) by Interferon (IFN) have not been fully elucidated, the 2"-5"-oligoadenylate (2-5A) system is one of the mechanisms of the antiviral effect of IFN. Ribavirin 111-120 interferon alpha 1 Homo sapiens 263-266 16958821-0 2006 2"-,5"-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. OBJECTIVE: Although all the mechanisms of elimination of hepatitis C virus (HCV) by Interferon (IFN) have not been fully elucidated, the 2"-5"-oligoadenylate (2-5A) system is one of the mechanisms of the antiviral effect of IFN. Ribavirin 111-120 interferon alpha 1 Homo sapiens 391-394 17066158-0 2006 Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Rare cases of ischemic colitis associated with interferon-alpha (IFN-alpha) treatment for chronic hepatitis C (HCV) infection and metastatic cancer have been reported. Ribavirin 55-64 interferon alpha 1 Homo sapiens 163-172 16633105-6 2006 Consideration is also given to evidence showing that treatment with ribavirin may contribute to IFN-induced depression. Ribavirin 68-77 interferon alpha 1 Homo sapiens 96-99 16780556-9 2006 CONCLUSIONS: Nonresponders to IFN monotherapy who achieve a sustained virologic response after retreatment with IFN + ribavirin stand a discrete risk of HCV reactivation within 2 yr after therapy. Ribavirin 118-127 interferon alpha 1 Homo sapiens 30-33 16980747-0 2006 Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C. The aim of the 18 months follow up study was to assess the frequency of anemia during IFN/RBV therapy in patients with chronic hepatitis C; to manage anemia either with recombinant human erythropoietin (rHuEPO)--epoetin alpha or with RBV dose reduction and to compare the rate of SVR in patients with RBV dose reduction and with administration of epoetin alpha. Ribavirin 191-194 interferon alpha 1 Homo sapiens 0-3 16980747-0 2006 Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C. The aim of the 18 months follow up study was to assess the frequency of anemia during IFN/RBV therapy in patients with chronic hepatitis C; to manage anemia either with recombinant human erythropoietin (rHuEPO)--epoetin alpha or with RBV dose reduction and to compare the rate of SVR in patients with RBV dose reduction and with administration of epoetin alpha. Ribavirin 335-338 interferon alpha 1 Homo sapiens 0-3 16980747-0 2006 Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C. The aim of the 18 months follow up study was to assess the frequency of anemia during IFN/RBV therapy in patients with chronic hepatitis C; to manage anemia either with recombinant human erythropoietin (rHuEPO)--epoetin alpha or with RBV dose reduction and to compare the rate of SVR in patients with RBV dose reduction and with administration of epoetin alpha. Ribavirin 335-338 interferon alpha 1 Homo sapiens 0-3 16618404-0 2006 Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Ribavirin 34-43 interferon alpha 1 Homo sapiens 66-76 16618404-0 2006 Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Ribavirin 77-86 interferon alpha 1 Homo sapiens 10-20 16618404-0 2006 Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Ribavirin 77-86 interferon alpha 1 Homo sapiens 66-76 16780556-1 2006 OBJECTIVES: To evaluate whether in chronic hepatitis C-positive patients who failed to respond to interferon (IFN) monotherapy a sustained response obtained with retreatment using the combination therapy of IFN + ribavirin can be safely considered to reflect eradication of the infection. Ribavirin 213-222 interferon alpha 1 Homo sapiens 110-113 16838649-4 2006 The most effective initial IFN therapy is the combination of pegylated IFN alpha-2b plus ribavirin. Ribavirin 89-98 interferon alpha 1 Homo sapiens 27-30 17364060-3 2006 Combination of IFN preparation with some nucleosides, including ribavirin, proved to be highly effective towards drug-resistant herpes virus. Ribavirin 64-73 interferon alpha 1 Homo sapiens 15-18 16733374-16 2006 Late secondary adjunction of ribavirin to IFN-alpha for 6 months in HCV-RNA negative patients after 6 months of IFN-alpha significantly decreases the relapse rate in patients with HCV genotype 2 or 3, but not in patients with genotypes 1, 4 or 5. Ribavirin 29-38 interferon alpha 1 Homo sapiens 112-121 16584394-11 2006 CONCLUSIONS: CIFN and ribavirin treatment induced considerable SVR rates in patients with non-response or relapse to IFNalpha+/-ribavirin. Ribavirin 22-31 interferon alpha 1 Homo sapiens 117-125 16462544-0 2006 Resolution of diabetes in type 2 diabetic patient treated with IFN-alpha and ribavirin for hepatitis C. We report on a patient whose type 2 diabetes mellitus resolved during IFN-alpha therapy for hepatitis C virus (HCV). Ribavirin 77-86 interferon alpha 1 Homo sapiens 174-183 16498048-1 2006 Autoimmune thyroid disease is a common side-effect of interferon-alpha (IFN-alpha) treatment of viral hepatitis C. We have described three patients with hepatitis C for whom IFN-alpha and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves" disease. Ribavirin 188-197 interferon alpha 1 Homo sapiens 72-81 16518956-2 2006 We investigated the expression of hepatic IFN receptor alpha/beta (IFNAR2c) mRNA and its association with the effectiveness of IFN plus ribavirin (RBV) therapy and with the clinical features in patients with HCV genotype 1b (HCV-1b) infection. Ribavirin 136-145 interferon alpha 1 Homo sapiens 42-45 16527653-2 2006 Similarly, relapsers after combination standard IFN and RBV therapy have higher SVR rates than combination of therapy nonresponders when treated with pegylated interferon and ribavirin. Ribavirin 175-184 interferon alpha 1 Homo sapiens 48-51 16538590-2 2006 The introduction of therapy with intraventricular interferon alpha (IFN-alpha) and its later association with ribavirin aroused new expectations. Ribavirin 110-119 interferon alpha 1 Homo sapiens 50-77 16493487-0 2006 Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis C. Interferon alpha (IFN-alpha) is used to treat haematological and solid malignancies and is the gold standard therapy for chronic hepatitis C infection in combination with ribavirin. Ribavirin 272-281 interferon alpha 1 Homo sapiens 119-128 16475995-7 2006 These results suggest that ribavirin may modulate the humoral immune response against HCV and trigger a favourable response to IFN. Ribavirin 27-36 interferon alpha 1 Homo sapiens 127-130 17310824-1 2006 Patients with chronic infection with the 3a genotype of hepatitis C virus (HCV) are considered as "easy-to-treat" with interferon/ribavirin (IFN/RBV), independent of liver disease severity. Ribavirin 130-139 interferon alpha 1 Homo sapiens 141-144 16518956-2 2006 We investigated the expression of hepatic IFN receptor alpha/beta (IFNAR2c) mRNA and its association with the effectiveness of IFN plus ribavirin (RBV) therapy and with the clinical features in patients with HCV genotype 1b (HCV-1b) infection. Ribavirin 136-145 interferon alpha 1 Homo sapiens 67-70 16518956-2 2006 We investigated the expression of hepatic IFN receptor alpha/beta (IFNAR2c) mRNA and its association with the effectiveness of IFN plus ribavirin (RBV) therapy and with the clinical features in patients with HCV genotype 1b (HCV-1b) infection. Ribavirin 147-150 interferon alpha 1 Homo sapiens 42-45 16518956-2 2006 We investigated the expression of hepatic IFN receptor alpha/beta (IFNAR2c) mRNA and its association with the effectiveness of IFN plus ribavirin (RBV) therapy and with the clinical features in patients with HCV genotype 1b (HCV-1b) infection. Ribavirin 147-150 interferon alpha 1 Homo sapiens 67-70 16166793-9 2006 Our study has demonstrated that mutations in the IFN sensitivity-determining region, spanning nucleotides 2,209-2,248 in the NS5A region, correlate with the sustained virological response to combination therapy with IFN and ribavirin in patients with chronic HCV-1b infection in Taiwan. Ribavirin 224-233 interferon alpha 1 Homo sapiens 49-52 16293442-0 2006 Early immune-mediated response to ribavirin combined with IFN in patients with chronic hepatitis C. AIM: This study was to investigate the immunomodulatory effects of ribavirin combined with interferon (IFN)-alpha 2b (R+IFN) compared with consensus IFN monotherapy (IFN-Con) in chronic hepatitis C (CHC) patients. Ribavirin 34-43 interferon alpha 1 Homo sapiens 203-206 16293442-0 2006 Early immune-mediated response to ribavirin combined with IFN in patients with chronic hepatitis C. AIM: This study was to investigate the immunomodulatory effects of ribavirin combined with interferon (IFN)-alpha 2b (R+IFN) compared with consensus IFN monotherapy (IFN-Con) in chronic hepatitis C (CHC) patients. Ribavirin 34-43 interferon alpha 1 Homo sapiens 203-206 16293442-0 2006 Early immune-mediated response to ribavirin combined with IFN in patients with chronic hepatitis C. AIM: This study was to investigate the immunomodulatory effects of ribavirin combined with interferon (IFN)-alpha 2b (R+IFN) compared with consensus IFN monotherapy (IFN-Con) in chronic hepatitis C (CHC) patients. Ribavirin 34-43 interferon alpha 1 Homo sapiens 203-206 16293442-0 2006 Early immune-mediated response to ribavirin combined with IFN in patients with chronic hepatitis C. AIM: This study was to investigate the immunomodulatory effects of ribavirin combined with interferon (IFN)-alpha 2b (R+IFN) compared with consensus IFN monotherapy (IFN-Con) in chronic hepatitis C (CHC) patients. Ribavirin 34-43 interferon alpha 1 Homo sapiens 203-206 16166797-4 2006 Addition of ribavirin to IFN increases the sustained virological response (SVR). Ribavirin 12-21 interferon alpha 1 Homo sapiens 25-28 16166797-11 2006 Combination therapy with peg-IFN and ribavirin accomplished higher SVR than conventional IFN and ribavirin. Ribavirin 37-46 interferon alpha 1 Homo sapiens 89-92 16758742-11 2006 Pegylated IFN alpha-2b with RBV seems to be effective in children with chronic hepatitis C previously non responded to therapy. Ribavirin 28-31 interferon alpha 1 Homo sapiens 10-13 16433196-9 2005 IFN monotherapy seems reasonable for patients with thalassemia and chronic hepatitis C virus in whom ribavirin cannot be used. Ribavirin 101-110 interferon alpha 1 Homo sapiens 0-3 16227297-2 2005 Patients are currently treated with alpha interferon (IFN-alpha) that is given alone or in combination with ribavirin. Ribavirin 108-117 interferon alpha 1 Homo sapiens 36-63 16084622-1 2005 BACKGROUND/AIMS: Differences in HCV-RNA clearance during therapy might explain the lower efficacy of peg-IFN/RBV in HIV/HCV-coinfection. Ribavirin 109-112 interferon alpha 1 Homo sapiens 105-108 16279900-5 2005 CONCLUSION: Combination therapy with PEG IFN alpha-2b plus RBV is more effective in patients who relapsed after combination standard IFN plus RBV than in nonresponders to either combination therapy or IFN monotherapy. Ribavirin 59-62 interferon alpha 1 Homo sapiens 41-44 16279900-5 2005 CONCLUSION: Combination therapy with PEG IFN alpha-2b plus RBV is more effective in patients who relapsed after combination standard IFN plus RBV than in nonresponders to either combination therapy or IFN monotherapy. Ribavirin 59-62 interferon alpha 1 Homo sapiens 133-136 16279900-5 2005 CONCLUSION: Combination therapy with PEG IFN alpha-2b plus RBV is more effective in patients who relapsed after combination standard IFN plus RBV than in nonresponders to either combination therapy or IFN monotherapy. Ribavirin 59-62 interferon alpha 1 Homo sapiens 133-136 16279900-5 2005 CONCLUSION: Combination therapy with PEG IFN alpha-2b plus RBV is more effective in patients who relapsed after combination standard IFN plus RBV than in nonresponders to either combination therapy or IFN monotherapy. Ribavirin 142-145 interferon alpha 1 Homo sapiens 41-44 16237717-6 2005 Treatment of recipients with histological recurrence is with pegylated IFN (+/- ribavirin). Ribavirin 80-89 interferon alpha 1 Homo sapiens 71-74 24790244-9 2005 At baseline, the IFN + RBV treatment group (330 patients) had significantly higher percentages of black patients (22.1% vs 15.7%; P = 0.032) and patients with hepatic disease based on clinician-reported cirrhosis and liver dysfunction (18.8% vs 9.9%; P < 0.001), and a significantly lower percentage of white patients (60.3% vs 69.6%; P = 0.012) compared with the peg-IFN + RBV treatment group (345 patients). Ribavirin 23-26 interferon alpha 1 Homo sapiens 371-374 24790244-18 2005 CONCLUSIONS: In this retrospective data analysis of US office-based practicesconcerning HCV treatment, clinicians were observed to prescribe IFN + RBV at doses that differ from recommendations in the product information (PI), as well as prescribe the RBV component of peg-IFN + RBV at doses that differed from PI recommendations. Ribavirin 251-254 interferon alpha 1 Homo sapiens 141-144 24790244-18 2005 CONCLUSIONS: In this retrospective data analysis of US office-based practicesconcerning HCV treatment, clinicians were observed to prescribe IFN + RBV at doses that differ from recommendations in the product information (PI), as well as prescribe the RBV component of peg-IFN + RBV at doses that differed from PI recommendations. Ribavirin 251-254 interferon alpha 1 Homo sapiens 141-144 24790244-9 2005 At baseline, the IFN + RBV treatment group (330 patients) had significantly higher percentages of black patients (22.1% vs 15.7%; P = 0.032) and patients with hepatic disease based on clinician-reported cirrhosis and liver dysfunction (18.8% vs 9.9%; P < 0.001), and a significantly lower percentage of white patients (60.3% vs 69.6%; P = 0.012) compared with the peg-IFN + RBV treatment group (345 patients). Ribavirin 377-380 interferon alpha 1 Homo sapiens 17-20 24764593-9 2005 RESULTS: Although standard IFN monotherapy failed to achieve virologic and hematologic improvement, therapy with pegylated IFN alfa-2a plus ribavirin was associated with both virologic and hematologic improvement without any significant adverse effects. Ribavirin 140-149 interferon alpha 1 Homo sapiens 123-126 15913800-0 2005 Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. The viral genotype and serum viral level influence the response to interferon (IFN) treatment in patients with chronic hepatitis C virus (HCV) viremia. Ribavirin 35-44 interferon alpha 1 Homo sapiens 221-231 15913800-0 2005 Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. The viral genotype and serum viral level influence the response to interferon (IFN) treatment in patients with chronic hepatitis C virus (HCV) viremia. Ribavirin 35-44 interferon alpha 1 Homo sapiens 233-236 15913800-0 2005 Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. The viral genotype and serum viral level influence the response to interferon (IFN) treatment in patients with chronic hepatitis C virus (HCV) viremia. Ribavirin 105-114 interferon alpha 1 Homo sapiens 221-231 15913800-0 2005 Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. The viral genotype and serum viral level influence the response to interferon (IFN) treatment in patients with chronic hepatitis C virus (HCV) viremia. Ribavirin 105-114 interferon alpha 1 Homo sapiens 233-236 16265606-7 2005 Drugs to replace or enhance ribavirin are being studied with IFN-based treatments. Ribavirin 28-37 interferon alpha 1 Homo sapiens 61-64 16161954-4 2005 In 25 cases treated with IFN ribavirin tests were repeated between 6-8 month of the therapy. Ribavirin 29-38 interferon alpha 1 Homo sapiens 25-28 15850468-9 2005 Daily 6 million units of IFN, six times/week for 2 weeks and then three times/week for 22 weeks were given with RBV (600-800 mg/day/patient). Ribavirin 112-115 interferon alpha 1 Homo sapiens 25-28 15756146-1 2005 In face of numerous benefits induced by therapy based on interferon (IFN) associated with ribavirin for the treatment of chronic hepatitis C, there is an increasing concern regarding its tolerance, which can, in some cases, reduce the quality of life as well as compliance of patients. Ribavirin 90-99 interferon alpha 1 Homo sapiens 57-67 15816475-0 2005 Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. BACKGROUND/AIMS: Recent large prospective trials demonstrated that the combination therapy of interferon (IFN)-alpha/ribavirin significantly increased a sustained virological response rate in patients with chronic hepatitis C. However, the potential mechanism of ribavirin is not clear. Ribavirin 46-55 interferon alpha 1 Homo sapiens 237-259 15816475-0 2005 Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. BACKGROUND/AIMS: Recent large prospective trials demonstrated that the combination therapy of interferon (IFN)-alpha/ribavirin significantly increased a sustained virological response rate in patients with chronic hepatitis C. However, the potential mechanism of ribavirin is not clear. Ribavirin 260-269 interferon alpha 1 Homo sapiens 237-259 15816475-0 2005 Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. BACKGROUND/AIMS: Recent large prospective trials demonstrated that the combination therapy of interferon (IFN)-alpha/ribavirin significantly increased a sustained virological response rate in patients with chronic hepatitis C. However, the potential mechanism of ribavirin is not clear. Ribavirin 260-269 interferon alpha 1 Homo sapiens 237-259 15756146-1 2005 In face of numerous benefits induced by therapy based on interferon (IFN) associated with ribavirin for the treatment of chronic hepatitis C, there is an increasing concern regarding its tolerance, which can, in some cases, reduce the quality of life as well as compliance of patients. Ribavirin 90-99 interferon alpha 1 Homo sapiens 69-72 15641150-9 2005 CONCLUSION: Combination regimen of interferon-alpha, ribavirin and amantadine can enhance sustained viral response on IFN-alpha and ribavirin non-responder patients with HCV. Ribavirin 53-62 interferon alpha 1 Homo sapiens 118-127 15699763-0 2005 Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C. BACKGROUND: HCV reinfection after liver transplantation is universal and has an accelerated course with a high risk of progression to cirrhosis. Ribavirin 49-58 interferon alpha 1 Homo sapiens 45-48 15699763-3 2005 We conducted a pilot study to determine the efficacy and safety of triple antiviral therapy in IFN-ribavirin nonresponders with recurrent chronic hepatitis C. METHODS: Twenty-four nonresponders to the IFN-ribavirin combination were enrolled in this pilot study. Ribavirin 99-108 interferon alpha 1 Homo sapiens 95-98 15699763-15 2005 CONCLUSION: Our results show that triple antiviral therapy for 48 weeks induced a sustained virological response in 33% of IFN-ribavirin nonresponders with recurrent hepatitis C. Ribavirin 127-136 interferon alpha 1 Homo sapiens 123-126 15828854-0 2005 Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. BACKGROUND: Interferon (IFN)-alpha and ribavirin combination therapy is the standard treatment for patients with chronic hepatitis C. However, ribavirin induces anaemia, especially by haemolysis, an adverse effect that is dose-limiting. Ribavirin 60-69 interferon alpha 1 Homo sapiens 122-144 16381243-1 2005 The most important therapeutic advance in recent years considering chronic HCV infection has occurred with the introduction of pegylated interferon (PEG IFN) in the combination therapy with ribavirin, which results in better sustained virologic response (SVR). Ribavirin 190-199 interferon alpha 1 Homo sapiens 153-156 15581735-6 2005 In addition, a 20-point or greater increase in SDS Index score during IFN-alpha/ribavirin therapy significantly predicted failure to clear virus when considered alone [crude odds ratio (OR), 3.2; 95% confidence interval (CI), 1.3-8.0; p <0.01] or when controlling for other factors that affected IFN-alpha treatment response (adjusted OR, 3.6; 95% CI, 1.3-9.5; p=0.01). Ribavirin 80-89 interferon alpha 1 Homo sapiens 299-308 15655043-5 2005 The combination of IFN plus ribavirin increases sustained virological response rates compared with IFN alone. Ribavirin 28-37 interferon alpha 1 Homo sapiens 99-102 15566510-1 2004 UNLABELLED: With the favorable result of interferon (IFN)-ribavirin combination therapy for 24 weeks among naive Taiwanese chronic hepatitis C (CHC) patients, the optimal regimens of re-treatment for CHC patients who failed initial IFN monotherapy is not well-established. Ribavirin 58-67 interferon alpha 1 Homo sapiens 53-56 15566510-1 2004 UNLABELLED: With the favorable result of interferon (IFN)-ribavirin combination therapy for 24 weeks among naive Taiwanese chronic hepatitis C (CHC) patients, the optimal regimens of re-treatment for CHC patients who failed initial IFN monotherapy is not well-established. Ribavirin 58-67 interferon alpha 1 Homo sapiens 232-235 15350490-3 2004 The main aim of this pilot study was to assess the efficacy of combined alpha-interferon (alpha-IFN) and ribavirin treatment of HCV hemodialysis (HDx) patients, by comparing the sustained virological response to that obtained by local historical data on treatment with alpha-IFN alone. Ribavirin 105-114 interferon alpha 1 Homo sapiens 275-278 15500548-5 2004 The HCV replication was inhibited by alpha-IFN 2b (7.39-13.2% at 10 U/mL, 3.29-6.12% at 100 U/mL, 1.3-4.86% at 1000 U/mL) and by ribavirin (4.36-13.9% at 100 microg/mL), but not by the other drugs at 24-72 h after treatment. Ribavirin 129-138 interferon alpha 1 Homo sapiens 43-46 15500555-0 2004 A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. Ribavirin 61-70 interferon alpha 1 Homo sapiens 113-123 15330905-3 2004 We sought to evaluate the efficacy of two doses of interferon alfa-2b (IFN) with ribavirin (RBV) in patients with normal ALT [correction]. Ribavirin 81-90 interferon alpha 1 Homo sapiens 71-74 15324941-2 2004 Several studies have assessed the efficacy of pegylated interferon (IFN) and ribavirin (RBV) combination therapy in IFN and RBV therapy relapsers. Ribavirin 77-86 interferon alpha 1 Homo sapiens 116-119 15324941-2 2004 Several studies have assessed the efficacy of pegylated interferon (IFN) and ribavirin (RBV) combination therapy in IFN and RBV therapy relapsers. Ribavirin 88-91 interferon alpha 1 Homo sapiens 116-119 15324941-2 2004 Several studies have assessed the efficacy of pegylated interferon (IFN) and ribavirin (RBV) combination therapy in IFN and RBV therapy relapsers. Ribavirin 124-127 interferon alpha 1 Homo sapiens 56-66 15324941-2 2004 Several studies have assessed the efficacy of pegylated interferon (IFN) and ribavirin (RBV) combination therapy in IFN and RBV therapy relapsers. Ribavirin 124-127 interferon alpha 1 Homo sapiens 68-71 15357651-10 2004 In patients with HCV genotype 1 and high viral loads, the effects of ribavirin with IFN-alpha appeared slowly, after the earliest days of treatment. Ribavirin 69-78 interferon alpha 1 Homo sapiens 84-93 15230850-4 2004 The combination of pegylated IFNa and ribavirin seems to be a rational approach for patients who failed to respond to IFNa monotherapy. Ribavirin 38-47 interferon alpha 1 Homo sapiens 118-122 15230850-5 2004 Pegylated IFNa-based regimens appear to induce sustained responses in 40-68% of relapsers but in only 11% of nonresponders to previous therapy with standard IFNa plus ribavirin. Ribavirin 167-176 interferon alpha 1 Homo sapiens 10-14 15350490-15 2004 CONCLUSION: This pilot study suggests that combination treatment for 24 weeks and 48 weeks with 3 MU alpha-IFN and 200 mg ribavirin three times a week, elicited a sustained virologic response in HDx patients with HCV infection better than IFN alone with minimal side effects. Ribavirin 122-131 interferon alpha 1 Homo sapiens 239-242 15163430-1 2004 Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) and ribavirin improves the rate of eradication of HCV, but only about 13-14% of non-responders (NR) with HCV of genotype 1b previously treated with IFN achieve a sustained virological response (SVR). Ribavirin 81-90 interferon alpha 1 Homo sapiens 225-228 15309891-0 2004 Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Acute pancreatitis is a rare complication of interferon (IFN) and ribavirin (RBV) therapy. Ribavirin 50-59 interferon alpha 1 Homo sapiens 151-161 15309891-0 2004 Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Acute pancreatitis is a rare complication of interferon (IFN) and ribavirin (RBV) therapy. Ribavirin 50-59 interferon alpha 1 Homo sapiens 163-166 15309891-0 2004 Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Acute pancreatitis is a rare complication of interferon (IFN) and ribavirin (RBV) therapy. Ribavirin 172-181 interferon alpha 1 Homo sapiens 35-45 15309891-0 2004 Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Acute pancreatitis is a rare complication of interferon (IFN) and ribavirin (RBV) therapy. Ribavirin 183-186 interferon alpha 1 Homo sapiens 35-45 15117324-2 2004 We analysed amino acid sequences of the viral RNA-dependent RNA polymerase (RdRP) or nonstructural protein 5B (NS5B), responsible for ribavirin misincorporation into RNA products in patients with genotype 1b-related chronic hepatitis C and high viremia, and examined the relationship between such RdRp polymorphisms, and the initial decline in viral load induced by combination therapy with IFN-alpha and ribavirin. Ribavirin 134-143 interferon alpha 1 Homo sapiens 391-394 15251366-8 2004 In three patients anemia necessitated administration of erythropoietin and three patients received granulocyte-colony stimulating factor (G-CSF) due to leucopenia [corrected] In conclusion, we observed that daily IFN alpha-2b and subsequent PEG IFN alpha-2b therapy in combination with ribavirin provides biochemical and virological benefits in transplant recipients with established recurrent HCV infection. Ribavirin 286-295 interferon alpha 1 Homo sapiens 213-216 14969836-14 2004 CONCLUSION: Daily IFN dosage with ribavirin is safe and can achieve response in up to 65% patients. Ribavirin 34-43 interferon alpha 1 Homo sapiens 18-21 15185728-9 2004 Since WNV-infected patients have already been treated with IFN and ribavirin and future clinical trials have been suggested, this first report of IFN alone or in combination with ribavirin in WNV-infected animal models might provide useful information for subsequent treatment of patients. Ribavirin 67-76 interferon alpha 1 Homo sapiens 146-149 14988824-6 2004 Ribavirin antiviral effect partly reduced the rebound preceding the second IFN-alpha injection in patients receiving standard IFN-alpha 3 times per week plus ribavirin. Ribavirin 0-9 interferon alpha 1 Homo sapiens 75-84 14988824-6 2004 Ribavirin antiviral effect partly reduced the rebound preceding the second IFN-alpha injection in patients receiving standard IFN-alpha 3 times per week plus ribavirin. Ribavirin 0-9 interferon alpha 1 Homo sapiens 126-135 14988824-10 2004 CONCLUSIONS: Ribavirin exerts a significant, moderate, and transient antiviral effect in a significant proportion of patients with chronic hepatitis C. The antiviral effect of ribavirin correlates with ribavirin pharmacokinetics and is partly responsible for the improved efficacy of the combination of standard IFN-alpha and ribavirin compared with IFN-alpha monotherapy by increasing the incidence of the initial response. Ribavirin 13-22 interferon alpha 1 Homo sapiens 312-321 14988824-10 2004 CONCLUSIONS: Ribavirin exerts a significant, moderate, and transient antiviral effect in a significant proportion of patients with chronic hepatitis C. The antiviral effect of ribavirin correlates with ribavirin pharmacokinetics and is partly responsible for the improved efficacy of the combination of standard IFN-alpha and ribavirin compared with IFN-alpha monotherapy by increasing the incidence of the initial response. Ribavirin 13-22 interferon alpha 1 Homo sapiens 350-359 14988824-10 2004 CONCLUSIONS: Ribavirin exerts a significant, moderate, and transient antiviral effect in a significant proportion of patients with chronic hepatitis C. The antiviral effect of ribavirin correlates with ribavirin pharmacokinetics and is partly responsible for the improved efficacy of the combination of standard IFN-alpha and ribavirin compared with IFN-alpha monotherapy by increasing the incidence of the initial response. Ribavirin 176-185 interferon alpha 1 Homo sapiens 312-321 14988824-10 2004 CONCLUSIONS: Ribavirin exerts a significant, moderate, and transient antiviral effect in a significant proportion of patients with chronic hepatitis C. The antiviral effect of ribavirin correlates with ribavirin pharmacokinetics and is partly responsible for the improved efficacy of the combination of standard IFN-alpha and ribavirin compared with IFN-alpha monotherapy by increasing the incidence of the initial response. Ribavirin 176-185 interferon alpha 1 Homo sapiens 350-359 15031779-8 2004 Our results suggest that the direct effects of ribavirin on the genetic stability of the HCV subgenome and its synergistic action combined, with IFN-alpha, may explain the improved clinical responses to combination therapy. Ribavirin 47-56 interferon alpha 1 Homo sapiens 145-154 15192274-8 2004 CONCLUSIONS: In PEG-IFN alpha-2b and ribavirin combination therapy, elimination of infected cells may be pronounced following an increase in serum ribavirin concentration in chronic hepatitis C patients with genotype 1b infection and a high viral load. Ribavirin 147-156 interferon alpha 1 Homo sapiens 20-23 15571424-12 2004 CONCLUSION: The combination of IL-2 and ribavirin seems to increase the probability of a sustained biochemical and virologic response in patients with chronic hepatitis C that is unresponsive to IFN. Ribavirin 40-49 interferon alpha 1 Homo sapiens 195-198 15279546-7 2004 Combination therapy with ribavirin does not seem to increase the response rate but could be proposed as a second choice to patients non responding to IFN monotherapy. Ribavirin 25-34 interferon alpha 1 Homo sapiens 150-153 15279549-0 2004 Artificial neural networks for the prediction of response to interferon plus ribavirin treatment in patients with chronic hepatitis C. Combined therapy using Interferon alfa (IFN) and Ribavirin (RIB) represents the standard treatment in patients with chronic hepatitis C. However, the percentage of responders to this regimen is still low, while its cost and side effects are elevated. Ribavirin 77-86 interferon alpha 1 Homo sapiens 175-178 14720084-8 2004 In the last 2 years, IFN plus ribavirin combination therapy has been the standard care for the treatment of chronic hepatitis C. Although information on the safety and efficacy of this dual therapy in HCV/HIV co-infected patients is scarce, recent trials have reported that the combination of IFN plus ribavirin is well tolerated and feasible in patients co-infected with HCV/HIV. Ribavirin 30-39 interferon alpha 1 Homo sapiens 293-296 14720084-8 2004 In the last 2 years, IFN plus ribavirin combination therapy has been the standard care for the treatment of chronic hepatitis C. Although information on the safety and efficacy of this dual therapy in HCV/HIV co-infected patients is scarce, recent trials have reported that the combination of IFN plus ribavirin is well tolerated and feasible in patients co-infected with HCV/HIV. Ribavirin 302-311 interferon alpha 1 Homo sapiens 21-24 14720084-8 2004 In the last 2 years, IFN plus ribavirin combination therapy has been the standard care for the treatment of chronic hepatitis C. Although information on the safety and efficacy of this dual therapy in HCV/HIV co-infected patients is scarce, recent trials have reported that the combination of IFN plus ribavirin is well tolerated and feasible in patients co-infected with HCV/HIV. Ribavirin 302-311 interferon alpha 1 Homo sapiens 293-296 15015227-7 2004 In patients who were administered the combination of alpha-IFN and ribavirin this effect appeared in 4 from 7 cases without history of treatment with alpha-IFN (57%), one from 2 relapses and one from 3 non-responders. Ribavirin 67-76 interferon alpha 1 Homo sapiens 156-159 15069622-9 2004 CONCLUSIONS: The efficacy of 24-week combination therapy of high-dose IFN alpha-2b induction and ribavirin deserves attention in HCV genotype 1b patients with a high viral load, especially in nonresponders to previous IFN monotherapy and patients with a very high viral load. Ribavirin 97-106 interferon alpha 1 Homo sapiens 218-221 15015227-8 2004 The combination PEG-IFN and ribavirin was effective in the only one patient who relapsed after alpha-IFN and ribavirin and in one from the two non-responders to this combination. Ribavirin 28-37 interferon alpha 1 Homo sapiens 101-104 15015227-8 2004 The combination PEG-IFN and ribavirin was effective in the only one patient who relapsed after alpha-IFN and ribavirin and in one from the two non-responders to this combination. Ribavirin 109-118 interferon alpha 1 Homo sapiens 20-23 14638410-1 2003 The approval of ribavirin in combination therapy regimens with interferon (IFN) dramatically improved therapy. Ribavirin 16-25 interferon alpha 1 Homo sapiens 75-78 14633182-1 2003 The complex immunological effects of interferon and ribavirin therapy (IFN/R) in hepatitis C virus (HCV) may also exacerbate or trigger the de novo development of autoimmunity. Ribavirin 52-61 interferon alpha 1 Homo sapiens 71-74 14662112-5 2003 Treatment with C-IFN lead to a higher response rate compared to that of recombinant IFN-alpha 2b in association with ribavirin. Ribavirin 117-126 interferon alpha 1 Homo sapiens 84-93 14988669-8 2003 In aged patients with chronic hepatitis C treatment with the more effective pegylated IFN should be taken into consideration, especially when association with ribavirin is at high risk of adverse events. Ribavirin 159-168 interferon alpha 1 Homo sapiens 86-89 14603150-7 2003 In contrast to non-HCV-infected recipients, treatment for acute cellular rejection is associated with attenuated patient survival among recipients with hepatitis C. Therapy with pegylated IFN (+/- ribavirin), although less efficacious than in immunocompetent patients, should be considered in recipients with histologically apparent recurrence of hepatitis C before jaundice develops. Ribavirin 197-206 interferon alpha 1 Homo sapiens 188-191 12969190-6 2003 Combination of IFN/ribavirin for 48 weeks is more effective when IFN is administered daily for the first 24 weeks in naive patients with CHC. Ribavirin 19-28 interferon alpha 1 Homo sapiens 65-68 12700452-12 2003 CONCLUSION: Treatment with peg-IFN and ribavirin is relatively well-tolerated in HIV/HCV-co-infected patients, although new side-effects, including pancreatitis and severe weight loss, may result from the interaction of ribavirin with antiretroviral drugs. Ribavirin 220-229 interferon alpha 1 Homo sapiens 31-34 15156609-0 2003 Assessment of selected clinical factors as predictors of response to combined interferon-alpha plus ribavirin therapy among patients with chronic hepatitis C. BACKGROUND: Combined interferon-alpha (IFN) plus ribavirin therapy is recommended as first-line regimen treatment of chronic hepatitis C (CHC) patients. Ribavirin 100-109 interferon alpha 1 Homo sapiens 198-201 15156609-1 2003 The aim of the study was to evaluate the selected clinical factors in the prediction of response to IFN with ribavirin for initial therapy and retreatment of CHC. Ribavirin 109-118 interferon alpha 1 Homo sapiens 100-103 12875209-10 2003 Early administration of intraventricular ribavirin and IFN might be considered especially to IFN in non-responders. Ribavirin 41-50 interferon alpha 1 Homo sapiens 93-96 12734046-7 2003 However, published reports describe treatment with IFN monotherapy and combination therapy with IFN and ribavirin. Ribavirin 104-113 interferon alpha 1 Homo sapiens 51-54 12753341-13 2003 In low viraemic patients who relapsed to a previous IFN treatment, combination therapy using high-dose IFN and low-dose ribavirin is better than high-dose IFN alone. Ribavirin 120-129 interferon alpha 1 Homo sapiens 52-55 12910808-5 2003 Later, it started the experimentations with IFN associated to other substances, for example IFN-ribavirin combination therapy. Ribavirin 96-105 interferon alpha 1 Homo sapiens 44-47 12910808-5 2003 Later, it started the experimentations with IFN associated to other substances, for example IFN-ribavirin combination therapy. Ribavirin 96-105 interferon alpha 1 Homo sapiens 92-95 12910808-6 2003 The treatment IFN-Ribavirin eradicates the infection in 30% of the patients with the genotype 1b and in 60% with the genotype 2 or 3, while this treatment is less efficacious in the patients with the genotype 4. Ribavirin 18-27 interferon alpha 1 Homo sapiens 14-17 12772791-10 2003 Interferon (IFN) ribavirin combination therapy is effective in patients with normal ALTs and appears superior to IFN monotherapy. Ribavirin 17-26 interferon alpha 1 Homo sapiens 12-15 12719586-10 2003 In a second group, ribavirin further up-regulated a set of RSV- and IFN-stimulated response genes (ISGs) encoding antiviral proteins (MxA and p56), complement products, acute-phase response factors, and the STAT and IRF transcription factors. Ribavirin 19-28 interferon alpha 1 Homo sapiens 68-71 12719586-11 2003 Because IFN-beta expression itself was reduced in the ribavirin-treated cells, we further investigated the mechanism for up-regulation of the IFN-signaling pathway. Ribavirin 54-63 interferon alpha 1 Homo sapiens 8-11 12719586-13 2003 Ribavirin-enhanced TAP-1-LMP2 expression was a transcriptional event where site mutations of the IFN-stimulated response element (ISRE) blocked RSV and ribavirin-inducible promoter activity. Ribavirin 0-9 interferon alpha 1 Homo sapiens 97-100 12719586-13 2003 Ribavirin-enhanced TAP-1-LMP2 expression was a transcriptional event where site mutations of the IFN-stimulated response element (ISRE) blocked RSV and ribavirin-inducible promoter activity. Ribavirin 152-161 interferon alpha 1 Homo sapiens 97-100 12719586-16 2003 We conclude that ribavirin potentiates virus-induced ISRE signaling to enhance the expression of antiviral ISGs, suggesting a mechanism for the efficacy of combined treatment with ribavirin and IFN in other chronic viral diseases. Ribavirin 17-26 interferon alpha 1 Homo sapiens 194-197 12691700-1 2003 The combined interferon-alpha (IFN-alpha) and ribavirin (IFN-alpha/ribavirin) therapy for chronic hepatitis C virus (HCV) infection results in sustained viral eradication in 31%-64% of the patients. Ribavirin 46-55 interferon alpha 1 Homo sapiens 57-66 12691700-3 2003 The objective of this study was to further define the effect of IFN-alpha/ribavirin therapy on type 1 and type 2 HCV-specific CD4(+) and CD8(+) T-cell responses during IFN-alpha/ribavirin therapy. Ribavirin 74-83 interferon alpha 1 Homo sapiens 168-177 12691700-3 2003 The objective of this study was to further define the effect of IFN-alpha/ribavirin therapy on type 1 and type 2 HCV-specific CD4(+) and CD8(+) T-cell responses during IFN-alpha/ribavirin therapy. Ribavirin 178-187 interferon alpha 1 Homo sapiens 64-73 12691700-7 2003 These results indicate that enhancement of HCV-specific CD4(+) and CD8(+) T-cell responses is an important factor in determining the response to the IFN-alpha/ribavirin therapy and the outcome of the HCV infection. Ribavirin 159-168 interferon alpha 1 Homo sapiens 149-158 12753337-7 2003 In conclusion, re-treatment of patients not responding to previous IFN monotherapy with a combination of high daily dose of IFN with ribavirin may be beneficial for genotype 1 infected patients. Ribavirin 133-142 interferon alpha 1 Homo sapiens 67-70 12753337-7 2003 In conclusion, re-treatment of patients not responding to previous IFN monotherapy with a combination of high daily dose of IFN with ribavirin may be beneficial for genotype 1 infected patients. Ribavirin 133-142 interferon alpha 1 Homo sapiens 124-127 12753338-1 2003 Interferon-alpha (IFN) monotherapy results in sustained virological clearance in a minority of patients with chronic hepatitis C. The aim of this study was to assess the effect of a reinforced regimen combining ribavirin and high-dose IFN for 48 weeks compared with a nonreinforced regimen combining a standard IFN regimen and ribavirin for 24 weeks in nonresponders with chronic hepatitis C. A total of 231 patients with chronic hepatitis C and previous nonresponse to IFN monotherapy were randomized. Ribavirin 211-220 interferon alpha 1 Homo sapiens 18-21 12753338-9 2003 Hence in nonresponders, a high-dose 48-week regimen of IFN and ribavirin combination was more effective than a regimen with interferon at lower dose and ribavirin for 24 weeks only. Ribavirin 153-162 interferon alpha 1 Homo sapiens 55-58 12753339-1 2003 Chronic hepatitis C patients with genotype 1 infection, liver cirrhosis, high viral load, or those who have not responded to anti-viral treatment in the past have limited chances of clearing the virus, even with pegylated interferon-ribavirin therapy. Ribavirin 233-242 interferon alpha 1 Homo sapiens 222-232 12471573-5 2002 Induction therapy and the dose of IFN should be evaluated in combination therapy with IFN and ribavirin. Ribavirin 94-103 interferon alpha 1 Homo sapiens 34-37 12702132-1 2003 OBJECTIVE: The effects on T-lymphocyte populations of two interferon-alfa-2a (IFN) regimens associated with ribavirin were evaluated in 36 HCV-HIV co-infected patients with chronic hepatitis C, T-CD4 cell count > 250 cells/ micro L and a plasma viral load of < 10 000 HIV RNA copies/mL. Ribavirin 108-117 interferon alpha 1 Homo sapiens 78-81 12934167-9 2003 Retreatment of nonresponders to standard IFN monotherapy using PEG-IFN and ribavirin has achieved SVR rates of 34 to 40%. Ribavirin 75-84 interferon alpha 1 Homo sapiens 41-44 12934167-11 2003 A SVR after retreatment of relapsers and nonresponders with PEG-IFN and ribavirin is more likely in patients previously treated with IFN monotherapy, those with HCV genotypes 2 or 3, patients with low viral load (<2 million copies/mL), and individuals who had a significant decrease in HCV RNA levels during the initial treatment. Ribavirin 72-81 interferon alpha 1 Homo sapiens 133-136 12614467-1 2003 Retreatment of relapser patients with chronic hepatitis C with the standard dose of interferon (IFN) of 3 million units (MU) thrice weekly (tiw) plus ribavirin for 24 weeks achieves a sustained response in 30 and 73% of patients with genotype 1 and 2 or 3, respectively. Ribavirin 150-159 interferon alpha 1 Homo sapiens 84-94 12614467-1 2003 Retreatment of relapser patients with chronic hepatitis C with the standard dose of interferon (IFN) of 3 million units (MU) thrice weekly (tiw) plus ribavirin for 24 weeks achieves a sustained response in 30 and 73% of patients with genotype 1 and 2 or 3, respectively. Ribavirin 150-159 interferon alpha 1 Homo sapiens 96-99 12427791-2 2002 METHODS: To assess the effectiveness and tolerability of IFN/ribavirin retreatment of non-responders to IFN and to identify predictors of complete (biochemical and virological) sustained response, we performed a meta-analysis of individual data on 581 patients from 10 centres. Ribavirin 61-70 interferon alpha 1 Homo sapiens 104-107 12297844-0 2002 A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Ribavirin 64-73 interferon alpha 1 Homo sapiens 144-154 12410649-6 2002 Our study shows that IFN and ribavirin combination therapy is effective in HIV-negative chronically HCV-infected haemophiliacs who do not respond to a previous IFN treatment. Ribavirin 29-38 interferon alpha 1 Homo sapiens 160-163 11952719-2 2002 Subsequently, a combination of IFN-alpha plus ribavirin showed a greater efficacy: up to 40% success with 3 MU of IFN-alpha three times weekly and 1000-1200 mg of ribavirin daily in naive patients and in those who had relapsed after a course of IFN-alpha therapy. Ribavirin 46-55 interferon alpha 1 Homo sapiens 114-123 12353832-0 2002 Retreatment of high-dose interferon (5 MU daily) nonresponders with high-dose IFN + ribavirin. Ribavirin 84-93 interferon alpha 1 Homo sapiens 25-35 12352634-12 2002 In our series, there is limited experience with IFN-ribavirin therapy, which was not well tolerated. Ribavirin 52-61 interferon alpha 1 Homo sapiens 48-51 12199910-7 2002 CONCLUSION: Although our results demonstrated a very poor outcome and a bad tolerance to interferon monotherapy, this approach should not be dropped out, mainly in patients at high risk for side effects and in those with cirrhosis who do not tolerate or are at increased risk for the use of ribavirin. Ribavirin 291-300 interferon alpha 1 Homo sapiens 89-99 12127430-1 2002 BACKGROUND/AIMS: Interferon (IFN) with ribavirin combination therapy (CT) was proposed for the treatment of hepatitis C recurring in liver transplants. Ribavirin 39-48 interferon alpha 1 Homo sapiens 29-32 12001034-3 2002 With combination interferon (IFN)-alpha 2b/ribavirin or pegylated IFN-alpha 2b/ribavirin therapy, long-term remission is possible for HCV-infected patients. Ribavirin 79-88 interferon alpha 1 Homo sapiens 66-75 12084032-17 2002 CONCLUSION: : Daily administration of IFN with ribavirin is well tolerated in the majority of patients. Ribavirin 47-56 interferon alpha 1 Homo sapiens 38-41 12352634-16 2002 Experience with IFN-ribavirin in this entity is limited, but has shown promise in hepatic disease and has shown efficacy in HCV-associated cryoglobulinemia. Ribavirin 20-29 interferon alpha 1 Homo sapiens 16-19 11870386-2 2002 All treatments known so far rely on the antiviral activity of interferon alfa (IFN-alpha) that is given alone or in combination with ribavirin. Ribavirin 133-142 interferon alpha 1 Homo sapiens 79-88 11952719-2 2002 Subsequently, a combination of IFN-alpha plus ribavirin showed a greater efficacy: up to 40% success with 3 MU of IFN-alpha three times weekly and 1000-1200 mg of ribavirin daily in naive patients and in those who had relapsed after a course of IFN-alpha therapy. Ribavirin 46-55 interferon alpha 1 Homo sapiens 114-123 11952719-2 2002 Subsequently, a combination of IFN-alpha plus ribavirin showed a greater efficacy: up to 40% success with 3 MU of IFN-alpha three times weekly and 1000-1200 mg of ribavirin daily in naive patients and in those who had relapsed after a course of IFN-alpha therapy. Ribavirin 163-172 interferon alpha 1 Homo sapiens 31-40 11937769-10 2002 Pharmacokinetic analysis of ribavirin provides information on its mechanism of action and for developing more rational treatment for IFN-resistant HCV. Ribavirin 28-37 interferon alpha 1 Homo sapiens 133-136 11803170-9 2002 Lastly, triple therapy with IFN, ribavirin and amantadine has been studied in small clinical trials in nonresponders to IFN monotherapy, with controversial results since in some studies sustained response was up to 48% being less than 20% in other studies. Ribavirin 33-42 interferon alpha 1 Homo sapiens 120-123 11945143-1 2002 Approximately 60% of all patients with chronic hepatitis C (C-HCV) treated with standard interferon (IFN) treatment, i.e. combination of recombinant alpha IFN and ribavirin (RBV), are refractory to treatment. Ribavirin 163-172 interferon alpha 1 Homo sapiens 101-104 11945143-1 2002 Approximately 60% of all patients with chronic hepatitis C (C-HCV) treated with standard interferon (IFN) treatment, i.e. combination of recombinant alpha IFN and ribavirin (RBV), are refractory to treatment. Ribavirin 174-177 interferon alpha 1 Homo sapiens 101-104 11843062-6 2002 RESULTS: The sustained virological response rates (26 weeks after end of treatment) were 54% and 47% for patients receiving IFN induction/ribavirin and standard IFN/ribavirin, respectively (P = 0.35). Ribavirin 138-147 interferon alpha 1 Homo sapiens 124-127 11843062-8 2002 In patients infected with genotype 2b/3a IFN induction/ribavirin led to a sustained response rate of 80% as compared to 65% in the standard combination therapy group (P = 0.073). Ribavirin 55-64 interferon alpha 1 Homo sapiens 41-44 11794896-6 2001 A second patient with IFN alpha and ribavirin for 4 months because of chronic hepatitis C (after the failure of a first treatment with IFN alpha alone) was hospitalized for fever, arthralgias, erythema nodosa and modification of previous skin scars. Ribavirin 36-45 interferon alpha 1 Homo sapiens 135-144 11851906-1 2002 We report two patients with chronic hepatitis C, both nonresponders to a previous course of interferon (IFN), who developed or suffered an exacerbation of sarcoidosis while under treatment with IFN-alpha2a, ribavirin and amantadine. Ribavirin 207-216 interferon alpha 1 Homo sapiens 104-107 15553066-1 2002 There is a overview of actual regimens proposed for treatment of acute and chronic hepatitis C. The new formulations of interferon alpha obtained by pegylation--PEG-IFN-s have resulted in improved efficacy as monotherapy and in combination with ribavirin. Ribavirin 245-254 interferon alpha 1 Homo sapiens 165-168 11494545-1 2001 Ribavirin is a purine nucleoside analog that inhibits the replication of a wide range of DNA and RNA viruses, although ribavirin treatment dose not significantly decrease serum virus load in patients with chronic hepatitis C. Several lines of evidence from the randomized large-scale studies of USA and Europe indicate that combination therapy with ribavirin significantly enhances the sustained response rate of IFN therapy in major patient types with chronic hepatitis C. A recent trial in Japan also proved that the combination therapy is superior to IFN monotherapy. Ribavirin 0-9 interferon alpha 1 Homo sapiens 413-416 11678522-4 2001 Combination therapy with IFN-alpha and ribavirin has been found to be more efficacious than IFN-alpha alone. Ribavirin 39-48 interferon alpha 1 Homo sapiens 92-101 12825459-1 2001 Ribavirin, a nucleoside analog, used in combination with interferon-alpha (IFN alpha) results in a substantial improvement in the sustained virologic response in chronic hepatitis C. Identified antiviral mechanisms of action for ribavirin include: (i) inhibition of viral encoded polymerases; (ii) inhibition of genomic RNA capping; and (iii) inhibition of cellular encoded enzymes that control de novo synthesis of purine nucleosides. Ribavirin 0-9 interferon alpha 1 Homo sapiens 75-84 12825459-1 2001 Ribavirin, a nucleoside analog, used in combination with interferon-alpha (IFN alpha) results in a substantial improvement in the sustained virologic response in chronic hepatitis C. Identified antiviral mechanisms of action for ribavirin include: (i) inhibition of viral encoded polymerases; (ii) inhibition of genomic RNA capping; and (iii) inhibition of cellular encoded enzymes that control de novo synthesis of purine nucleosides. Ribavirin 229-238 interferon alpha 1 Homo sapiens 75-84 11471097-1 2001 This study assessed the use of ribavirin monotherapy to enhance sustained virologic response in hepatitis C virus (HCV)-infected patients who achieved virologic response to interferon (IFN)-ribavirin combination therapy. Ribavirin 31-40 interferon alpha 1 Homo sapiens 185-188 15973580-4 2001 In an international multicenter study of over 1000 treatment-naive patients with hepatitis C virus (HCV) infection, sustained virological response was found in 56% of patients who received PEGylated interferon (IFN) alpha-2a (Pegasys; F Hoffmann-La Roche) in combination with ribavirin (Virazole; ICN Pharmaceuticals), versus 45% in patients who received IFN alpha-2b and ribavirin therapy, and 30% of patients who received PEG. Ribavirin 276-285 interferon alpha 1 Homo sapiens 189-215 15973580-4 2001 In an international multicenter study of over 1000 treatment-naive patients with hepatitis C virus (HCV) infection, sustained virological response was found in 56% of patients who received PEGylated interferon (IFN) alpha-2a (Pegasys; F Hoffmann-La Roche) in combination with ribavirin (Virazole; ICN Pharmaceuticals), versus 45% in patients who received IFN alpha-2b and ribavirin therapy, and 30% of patients who received PEG. Ribavirin 276-285 interferon alpha 1 Homo sapiens 211-214 15973580-4 2001 In an international multicenter study of over 1000 treatment-naive patients with hepatitis C virus (HCV) infection, sustained virological response was found in 56% of patients who received PEGylated interferon (IFN) alpha-2a (Pegasys; F Hoffmann-La Roche) in combination with ribavirin (Virazole; ICN Pharmaceuticals), versus 45% in patients who received IFN alpha-2b and ribavirin therapy, and 30% of patients who received PEG. Ribavirin 287-295 interferon alpha 1 Homo sapiens 189-215 15973580-4 2001 In an international multicenter study of over 1000 treatment-naive patients with hepatitis C virus (HCV) infection, sustained virological response was found in 56% of patients who received PEGylated interferon (IFN) alpha-2a (Pegasys; F Hoffmann-La Roche) in combination with ribavirin (Virazole; ICN Pharmaceuticals), versus 45% in patients who received IFN alpha-2b and ribavirin therapy, and 30% of patients who received PEG. Ribavirin 287-295 interferon alpha 1 Homo sapiens 211-214 15973580-4 2001 In an international multicenter study of over 1000 treatment-naive patients with hepatitis C virus (HCV) infection, sustained virological response was found in 56% of patients who received PEGylated interferon (IFN) alpha-2a (Pegasys; F Hoffmann-La Roche) in combination with ribavirin (Virazole; ICN Pharmaceuticals), versus 45% in patients who received IFN alpha-2b and ribavirin therapy, and 30% of patients who received PEG. Ribavirin 372-381 interferon alpha 1 Homo sapiens 189-215 15973580-4 2001 In an international multicenter study of over 1000 treatment-naive patients with hepatitis C virus (HCV) infection, sustained virological response was found in 56% of patients who received PEGylated interferon (IFN) alpha-2a (Pegasys; F Hoffmann-La Roche) in combination with ribavirin (Virazole; ICN Pharmaceuticals), versus 45% in patients who received IFN alpha-2b and ribavirin therapy, and 30% of patients who received PEG. Ribavirin 372-381 interferon alpha 1 Homo sapiens 211-214 11431744-1 2001 To determine whether a higher dosage of interferon (IFN) associated with ribavirin and/or prolonged time of administration may improve therapeutic efficacy, we conducted a 4-arm randomized trial on patients with chronic hepatitis C not responding to one or more previous treatment courses with IFN monotherapy. Ribavirin 73-82 interferon alpha 1 Homo sapiens 40-50 11431744-1 2001 To determine whether a higher dosage of interferon (IFN) associated with ribavirin and/or prolonged time of administration may improve therapeutic efficacy, we conducted a 4-arm randomized trial on patients with chronic hepatitis C not responding to one or more previous treatment courses with IFN monotherapy. Ribavirin 73-82 interferon alpha 1 Homo sapiens 52-55 11471097-2 2001 Patients who had chronic HCV infection and prior relapse were retreated with IFN-ribavirin for 6 months. Ribavirin 81-90 interferon alpha 1 Homo sapiens 77-80 11494545-1 2001 Ribavirin is a purine nucleoside analog that inhibits the replication of a wide range of DNA and RNA viruses, although ribavirin treatment dose not significantly decrease serum virus load in patients with chronic hepatitis C. Several lines of evidence from the randomized large-scale studies of USA and Europe indicate that combination therapy with ribavirin significantly enhances the sustained response rate of IFN therapy in major patient types with chronic hepatitis C. A recent trial in Japan also proved that the combination therapy is superior to IFN monotherapy. Ribavirin 0-9 interferon alpha 1 Homo sapiens 554-557 11494545-2 2001 Thus, IFN-ribavirin combination is likely to become the antiviral therapy of choice for chronic hepatitis C. Ribavirin 10-19 interferon alpha 1 Homo sapiens 6-9 11230751-10 2001 This study suggests that the combination of IFN and ribavirin is a useful modality of therapy in patients with chronic hepatitis C who did not respond to IFN alone. Ribavirin 52-61 interferon alpha 1 Homo sapiens 154-157 11391542-5 2001 Incubation with IFN-alpha with and without ribavirin (2.2 microg/mL) significantly reduced cell surface-associated CD81 protein (83.9 +/- 10.3% of control; P =.003). Ribavirin 43-52 interferon alpha 1 Homo sapiens 16-25 11482039-0 2001 Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferon. Ribavirin 38-47 interferon alpha 1 Homo sapiens 99-109 11396525-0 2001 A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. BACKGROUND: Combination of interferon (IFN) alpha and ribavirin is considered the standard treatment for patients with chronic hepatitis C. While combination therapy is more effective than IFN alone, the optimal management of combination treatment remains uncertain. Ribavirin 92-101 interferon alpha 1 Homo sapiens 171-193 11396525-0 2001 A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. BACKGROUND: Combination of interferon (IFN) alpha and ribavirin is considered the standard treatment for patients with chronic hepatitis C. While combination therapy is more effective than IFN alone, the optimal management of combination treatment remains uncertain. Ribavirin 92-101 interferon alpha 1 Homo sapiens 183-186 11298134-0 2001 Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C. Recent studies in vitro and in animals have suggested that ribavirin may potentiate the antihepatitis C virus (HCV) activity of interferon-alpha (IFN-alpha) by up-modulating the production of T cell-derived cytokines, such as interleukin (IL)-2 and IFN-gamma, which play a key role in the cellular immune response against HCV. Ribavirin 15-24 interferon alpha 1 Homo sapiens 266-275 11298134-0 2001 Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C. Recent studies in vitro and in animals have suggested that ribavirin may potentiate the antihepatitis C virus (HCV) activity of interferon-alpha (IFN-alpha) by up-modulating the production of T cell-derived cytokines, such as interleukin (IL)-2 and IFN-gamma, which play a key role in the cellular immune response against HCV. Ribavirin 179-188 interferon alpha 1 Homo sapiens 266-275 11298134-2 2001 After 16 weeks of treatment, both the expression of IFN-gamma by activated T cells and the blood levels of IFN-gamma, were significantly reduced with respect to pretreatment values in patients treated with ribavirin and IFN-alpha but not in those undergoing treatment with IFN-alpha alone. Ribavirin 206-215 interferon alpha 1 Homo sapiens 273-282 11434597-11 2001 CONCLUSIONS: A combination of high-dose IFN with ribavirin induces a short-lasting complete response in about one-third of IFN-non-responders. Ribavirin 49-58 interferon alpha 1 Homo sapiens 123-126 11244158-4 2001 The aim of this study is to review our experience in the treatment of moderate to severe HCV recurrence with combination interferon-alpha2b and ribavirin (IFN/RIB). Ribavirin 144-153 interferon alpha 1 Homo sapiens 155-162 11322207-1 2001 BACKGROUND: In chronic hepatitis C the schedule of interferon (IFN), 3 MU thrice weekly (tiw) plus ribavirin (1000-1200 mg/daily) needs further evaluation, as IFN dosages >3 MU achieve better responses. Ribavirin 99-108 interferon alpha 1 Homo sapiens 159-162 11322207-6 2001 Using logistic regression analysis, IFN-ribavirin was the strongest predictor of response (X2 = 21.3; P = 0.0001). Ribavirin 40-49 interferon alpha 1 Homo sapiens 36-39 11233844-5 2001 Four of these were HCV RNA-negative at week 4 of IFN-RBV therapy and two of them had a transient early virological response (RNA-negative at weeks 4-8) to IFN alone. Ribavirin 53-56 interferon alpha 1 Homo sapiens 49-52 11130893-1 2001 Interferon (IFN) therapy (+/- ribavirin) is the only currently available treatment for chronic hepatitis C virus (HCV), but is not effective for a majority of patients. Ribavirin 30-39 interferon alpha 1 Homo sapiens 12-15 11253505-0 2001 Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. Ribavirin plus interferon-alpha (IFN alpha) combination has led to a marked advance in the treatment of IFN alpha-naive or relapser patients with chronic hepatitis C but was shown to be only marginally effective in IFN alpha-nonresponders. Ribavirin 80-89 interferon alpha 1 Homo sapiens 191-200 11253505-0 2001 Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. Ribavirin plus interferon-alpha (IFN alpha) combination has led to a marked advance in the treatment of IFN alpha-naive or relapser patients with chronic hepatitis C but was shown to be only marginally effective in IFN alpha-nonresponders. Ribavirin 158-167 interferon alpha 1 Homo sapiens 262-271 11253505-0 2001 Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. Ribavirin plus interferon-alpha (IFN alpha) combination has led to a marked advance in the treatment of IFN alpha-naive or relapser patients with chronic hepatitis C but was shown to be only marginally effective in IFN alpha-nonresponders. Ribavirin 158-167 interferon alpha 1 Homo sapiens 262-271 11233844-7 2001 Thus, addition of RBV to IFN increased both viral clearance during the first 12 weeks of therapy and the rate of sustained response. Ribavirin 18-21 interferon alpha 1 Homo sapiens 25-28 11132533-1 2000 Combination therapy with interferon-alpha (IFN alpha) plus Ribavirin has been shown to improve the response rate in patients with chronic hepatitis C as compared to IFN alpha alone. Ribavirin 59-68 interferon alpha 1 Homo sapiens 165-174 10722482-10 2000 Both VX-497 and ribavirin demonstrated additivity when coapplied with IFN-alpha, with VX-497 again being the more potent in this combination. Ribavirin 16-25 interferon alpha 1 Homo sapiens 70-79 11015548-3 2000 Combining IFN-alpha and ribavirin (RBV) has been shown to significantly improve the response in adult patients with chronic hepatitis C. The aim of this pilot study was to evaluate the efficacy and safety of a combined virostatic treatment with IFN-alpha and RBV in a small cohort of children and adolescents with chronic hepatitis C and previous malignancy. Ribavirin 35-38 interferon alpha 1 Homo sapiens 245-254 16498353-4 2000 Important recent therapeutic progress that surpasses and advances the results obtained with single IFN therapy is the combination of IFN with ribavirin, with which overall rates of response have increased three times compared to IFN monotherapy. Ribavirin 142-151 interferon alpha 1 Homo sapiens 99-102 10921396-4 2000 For patients who cannot tolerate the side effects of ribavirin, such as anaemia, IFN-alpha at 3 MU three times weekly for 48 weeks is preferred as the initial therapy. Ribavirin 53-62 interferon alpha 1 Homo sapiens 81-90 10921400-1 2000 The preferred treatment for patients with chronic hepatitis C, either treatment-naive, relapsers or nonresponders to IFN monotherapy, is now IFN-ribavirin combination treatment. Ribavirin 145-154 interferon alpha 1 Homo sapiens 141-144 18034536-12 2000 CONCLUSIONS: These results suggest that patients with chronic hepatitis C unresponsive to IFNalpha monotherapy could benefit from combination therapy with IFNalpha + ribavirin. Ribavirin 166-175 interferon alpha 1 Homo sapiens 90-98 11015548-3 2000 Combining IFN-alpha and ribavirin (RBV) has been shown to significantly improve the response in adult patients with chronic hepatitis C. The aim of this pilot study was to evaluate the efficacy and safety of a combined virostatic treatment with IFN-alpha and RBV in a small cohort of children and adolescents with chronic hepatitis C and previous malignancy. Ribavirin 24-33 interferon alpha 1 Homo sapiens 245-254 10839592-12 2000 CONCLUSION: Our results indicate that combination therapy with IFN and ribavirin is effective in 50% of cases in clearing serum HCV RNA and may thus provide effective means of therapy in HIV-HCV-coinfected patients as initial treatment or in patients who have previously failed IFN monotherapy. Ribavirin 71-80 interferon alpha 1 Homo sapiens 278-281 10613748-2 2000 UNLABELLED: Randomized trials have shown the enhancement of efficacy with interferon alfa-2b and ribavirin (IFN-R) in comparison with interferon monotherapy (IFN) as first line treatment of chronic hepatitis C. Further definition of response based on disease, patient, and treatment characteristics is needed to determine the degree of benefit for the various patient subgroups. Ribavirin 97-106 interferon alpha 1 Homo sapiens 108-111 10733558-1 2000 The antiviral drug ribavirin (RBV) is widely used in combination with interferon (IFN) in the treatment of chronic hepatitis C virus (HCV) infection. Ribavirin 19-28 interferon alpha 1 Homo sapiens 82-85 11093071-7 2000 Under prophylactic treatment with low-dose trimipramine (50 mg) or nefazodone (200 mg/day) therapy with IFN-alpha 3 x 3 mio IE/week was re-established after several months and again 2 years later adding ribavirin 1200 mg/day, a virustaticum. Ribavirin 203-212 interferon alpha 1 Homo sapiens 104-113 10581390-8 1999 Furthermore, suppression of IFN-induced 2-5AS induction and MHC class-I expression was restored by treatment of persistently infected cells with ribavirin through inhibition of virus replication. Ribavirin 145-154 interferon alpha 1 Homo sapiens 28-31 10581390-9 1999 The result of restoration was also confirmed by IFN-induced STAT-1 induction in persistently infected cells treated with ribavirin. Ribavirin 121-130 interferon alpha 1 Homo sapiens 48-51 11291251-12 1999 Also, the effect of ribavirin on IFN-mediated changes in HCV RNA levels needs to be investigated in carefully performed kinetics studies to better determine its mechanism of action. Ribavirin 20-29 interferon alpha 1 Homo sapiens 33-36 10616260-3 1999 This report documents the preliminary findings of an investigative protocol to evaluate the efficacy of long-term (12 month), daily IFN alpha 2b and ribavirin combination therapy for chronic hepatitis C patients, who have either relapsed (relapsers) or not responded (non-responders) to previous IFN therapy. Ribavirin 149-158 interferon alpha 1 Homo sapiens 296-299 10616260-9 1999 CONCLUSION: Although further studies on larger patient populations are necessary, our preliminary data suggests that daily IFN alpha 2b and ribavirin treatment is highly effective, especially among patients who have relapsed from previous IFN treatment. Ribavirin 140-149 interferon alpha 1 Homo sapiens 123-126 10616260-9 1999 CONCLUSION: Although further studies on larger patient populations are necessary, our preliminary data suggests that daily IFN alpha 2b and ribavirin treatment is highly effective, especially among patients who have relapsed from previous IFN treatment. Ribavirin 140-149 interferon alpha 1 Homo sapiens 239-242 10419923-2 1999 BACKGROUND & AIMS: The aim of this study was to compare interferon (IFN)-ribavirin combination therapy with IFN monotherapy in chronic hepatitis C with particular focus on its efficacy in cirrhosis. Ribavirin 77-86 interferon alpha 1 Homo sapiens 72-75 10438811-0 1999 Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. Alpha interferon (IFN-alpha) treatment is effective on a long-term basis in only 15 to 25% of patients with chronic hepatitis C. The results of recent trials indicate that response rates can be significantly increased when IFN-alpha is given in combination with ribavirin. Ribavirin 63-72 interferon alpha 1 Homo sapiens 174-201 10438811-0 1999 Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. Alpha interferon (IFN-alpha) treatment is effective on a long-term basis in only 15 to 25% of patients with chronic hepatitis C. The results of recent trials indicate that response rates can be significantly increased when IFN-alpha is given in combination with ribavirin. Ribavirin 63-72 interferon alpha 1 Homo sapiens 192-201 10438811-0 1999 Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. Alpha interferon (IFN-alpha) treatment is effective on a long-term basis in only 15 to 25% of patients with chronic hepatitis C. The results of recent trials indicate that response rates can be significantly increased when IFN-alpha is given in combination with ribavirin. Ribavirin 436-445 interferon alpha 1 Homo sapiens 174-201 10438811-0 1999 Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. Alpha interferon (IFN-alpha) treatment is effective on a long-term basis in only 15 to 25% of patients with chronic hepatitis C. The results of recent trials indicate that response rates can be significantly increased when IFN-alpha is given in combination with ribavirin. Ribavirin 436-445 interferon alpha 1 Homo sapiens 192-201 10419923-3 1999 METHODS: A multivariate analysis of individual patient data of all randomized controlled trials using an IFN-ribavirin arm, reported between 1991 and March 1998, was performed. Ribavirin 109-118 interferon alpha 1 Homo sapiens 105-108 10419923-8 1999 RESULTS: Patients without cirrhosis treated with IFN-ribavirin had a significantly higher sustained response rate than those treated with IFN, approximately 3-fold for previously untreated patients (IFN-ribavirin: genotype 1, 33%; genotype 2/3, 65%; IFN: genotype 1, 8%; genotype 2/3, 24%). Ribavirin 53-62 interferon alpha 1 Homo sapiens 49-52 10419923-9 1999 In cirrhosis, sustained response rates with IFN-ribavirin (previously untreated: genotype 1, 7%; genotype 2/3, 24%) were also significantly higher than those with IFN (previously untreated: genotype 1, 1%; genotype 2/3, 5%). Ribavirin 48-57 interferon alpha 1 Homo sapiens 44-47 10419923-11 1999 Tolerance for IFN-ribavirin was similar for patients with or without cirrhosis. Ribavirin 18-27 interferon alpha 1 Homo sapiens 14-17 10419923-12 1999 CONCLUSIONS: Combination with ribavirin significantly enhances the sustained response rate of IFN therapy in major patient types (cirrhosis, genotype 1) with chronic hepatitis C. Thus, IFN-ribavirin combination is likely to become the antiviral therapy of choice for cirrhosis caused by hepatitis C. Ribavirin 30-39 interferon alpha 1 Homo sapiens 94-97 10419923-12 1999 CONCLUSIONS: Combination with ribavirin significantly enhances the sustained response rate of IFN therapy in major patient types (cirrhosis, genotype 1) with chronic hepatitis C. Thus, IFN-ribavirin combination is likely to become the antiviral therapy of choice for cirrhosis caused by hepatitis C. Ribavirin 189-198 interferon alpha 1 Homo sapiens 94-97 10419923-12 1999 CONCLUSIONS: Combination with ribavirin significantly enhances the sustained response rate of IFN therapy in major patient types (cirrhosis, genotype 1) with chronic hepatitis C. Thus, IFN-ribavirin combination is likely to become the antiviral therapy of choice for cirrhosis caused by hepatitis C. Ribavirin 189-198 interferon alpha 1 Homo sapiens 185-188 10494606-1 1999 The influence of ribavirin on IFN-antibody formation in combination therapy with IFN-alpha has not yet been studied. Ribavirin 17-26 interferon alpha 1 Homo sapiens 30-33 10494606-2 1999 Therefore we evaluated the relationship between IFN-antibodies and response to ribavirin/IFN-alpha combination therapy and IFN-alpha monotherapy. Ribavirin 79-88 interferon alpha 1 Homo sapiens 48-51 10494606-13 1999 The development of high-titer IFN-antibodies during IFN-alpha or ribavirin/IFN-alpha therapy of patients with chronic hepatitis C may account for the early occurrence of breakthrough in some patients, while other mechanisms seem to be responsible for this phenomenon in the majority of the afflicted patients. Ribavirin 65-74 interferon alpha 1 Homo sapiens 30-33 10760037-10 1999 These data indicate that a combination of high-dose IFN with ribavirin is effective in inducing a short-lasting complete response in one-third of IFN nonresponders. Ribavirin 61-70 interferon alpha 1 Homo sapiens 146-149 10192200-12 1999 CONCLUSIONS: In a group of previous IFN-alpha2a-treated chronic HCV patients we obtained a similar sustained clearance of viremia when retreated either with IFN-alpha2a alone or with a combination of IFN-alpha2a and ribavirin for 6 months. Ribavirin 216-225 interferon alpha 1 Homo sapiens 36-39 10405886-13 1999 RESULTS: Only recently clinical data revealed a greater benefit of combination therapy with IFN-alpha and ribavirin compared to IFN-alpha alone in patients with chronic hepatitis C. In 345 CHC patients relapsing after pretreatment with IFN-alpha monotherapy, sustained response was achieved in a 10-fold higher degree with a combination of IFN and ribavirin compared to patients retreated with IFN alone. Ribavirin 348-357 interferon alpha 1 Homo sapiens 92-101 10405886-17 1999 The consequences for treatment options with IFN are a combination with ribavirin in CHC and a graduated systemic treatment schedule in AIDS-KS starting with IFN-treatment in early disease followed by chemotherapy in advanced stages of KS. Ribavirin 71-80 interferon alpha 1 Homo sapiens 44-47 10349692-0 1999 Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Interferon (IFN) results in normalization of the serum alanine aminotransferase (ALT), loss of detectable serum hepatitis C virus (HCV) RNA, and histologic improvement in approximately 40% of patients. Ribavirin 45-54 interferon alpha 1 Homo sapiens 73-83 10622581-4 1999 Ribavirin in combination with alpha interferon, in standard doses for 6-12 months significantly improves the sustained biochemical and virological response rates 2-3 times compared with IFN alone for 12 months. Ribavirin 0-9 interferon alpha 1 Homo sapiens 186-189 10349692-0 1999 Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Interferon (IFN) results in normalization of the serum alanine aminotransferase (ALT), loss of detectable serum hepatitis C virus (HCV) RNA, and histologic improvement in approximately 40% of patients. Ribavirin 45-54 interferon alpha 1 Homo sapiens 116-126 10349692-0 1999 Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Interferon (IFN) results in normalization of the serum alanine aminotransferase (ALT), loss of detectable serum hepatitis C virus (HCV) RNA, and histologic improvement in approximately 40% of patients. Ribavirin 45-54 interferon alpha 1 Homo sapiens 128-131 10349692-2 1999 Retreatment of IFN relapsers with the combination of IFN and oral ribavirin for 6 months results in end-of-treatment loss of detectable HCV RNA and normalization of the ALT level in over 80% of patients. Ribavirin 66-75 interferon alpha 1 Homo sapiens 15-18 9862245-9 1998 Ribavirin and IFN pharmacokinetic parameters for combined ribavirin and IFN were similar to those during monotherapy with either compound, although the power of this study to detect differences was low. Ribavirin 0-9 interferon alpha 1 Homo sapiens 72-75 9860407-1 1998 OBJECTIVE: The aim of the study was to assess the efficacy of interferon (IFN)-alpha-2b and ribavirin in combination in the treatment of chronic hepatitis C (CHC) patients unresponsive to a previous treatment with IFN-alpha-2b alone. Ribavirin 92-101 interferon alpha 1 Homo sapiens 214-223 9860407-9 1998 CONCLUSIONS: A 24-wk treatment course with IFN-alpha and ribavirin given to patients with a previous lack of response to IFN-alpha alone offers a chance of a sustained biochemical and virological response, at least in a subset of such patients. Ribavirin 57-66 interferon alpha 1 Homo sapiens 121-130 9862245-12 1998 IFN and ribavirin monotherapy produced characteristic changes in safety laboratory tests (IFN--reductions in white cells, neutrophils and platelets; ribavirin--reduced haemoglobin) and characteristic adverse event profiles (IFN--headache, flu-like symptoms, fatigue, anorexia, nausea, myalgia, and insomnia; ribavirin--headache, fatigue, myalgia, and pruritus). Ribavirin 149-158 interferon alpha 1 Homo sapiens 0-3 9862245-9 1998 Ribavirin and IFN pharmacokinetic parameters for combined ribavirin and IFN were similar to those during monotherapy with either compound, although the power of this study to detect differences was low. Ribavirin 58-67 interferon alpha 1 Homo sapiens 14-17 9862245-12 1998 IFN and ribavirin monotherapy produced characteristic changes in safety laboratory tests (IFN--reductions in white cells, neutrophils and platelets; ribavirin--reduced haemoglobin) and characteristic adverse event profiles (IFN--headache, flu-like symptoms, fatigue, anorexia, nausea, myalgia, and insomnia; ribavirin--headache, fatigue, myalgia, and pruritus). Ribavirin 8-17 interferon alpha 1 Homo sapiens 90-93 9862245-12 1998 IFN and ribavirin monotherapy produced characteristic changes in safety laboratory tests (IFN--reductions in white cells, neutrophils and platelets; ribavirin--reduced haemoglobin) and characteristic adverse event profiles (IFN--headache, flu-like symptoms, fatigue, anorexia, nausea, myalgia, and insomnia; ribavirin--headache, fatigue, myalgia, and pruritus). Ribavirin 8-17 interferon alpha 1 Homo sapiens 90-93 9862245-12 1998 IFN and ribavirin monotherapy produced characteristic changes in safety laboratory tests (IFN--reductions in white cells, neutrophils and platelets; ribavirin--reduced haemoglobin) and characteristic adverse event profiles (IFN--headache, flu-like symptoms, fatigue, anorexia, nausea, myalgia, and insomnia; ribavirin--headache, fatigue, myalgia, and pruritus). Ribavirin 149-158 interferon alpha 1 Homo sapiens 0-3 9407357-9 1997 The combined use of ribavirin or corticosteroid priming may improve the effect of IFN therapy by enhancing the durability of the response. Ribavirin 20-29 interferon alpha 1 Homo sapiens 82-85 9658373-10 1998 In conclusion, our results suggest that long-term administration of ribavirin is well tolerated and may be beneficial in controlling the progression of chronic hepatitis C. This may represent an alternative therapy in patients who have contraindications for interferon therapy or as a palliative approach in non-responders to IFN. Ribavirin 68-77 interferon alpha 1 Homo sapiens 258-268 9658373-10 1998 In conclusion, our results suggest that long-term administration of ribavirin is well tolerated and may be beneficial in controlling the progression of chronic hepatitis C. This may represent an alternative therapy in patients who have contraindications for interferon therapy or as a palliative approach in non-responders to IFN. Ribavirin 68-77 interferon alpha 1 Homo sapiens 326-329 9458644-7 1998 Patients with higher pre-treatment HCV RNA levels (> or = 3 million Eq/mL) and patients manifesting unsustained response to earlier IFN treatment should receive combination treatment with ribavirin and IFN-alpha, as treatment with IFN alone is associated with poor chances of sustained response. Ribavirin 191-200 interferon alpha 1 Homo sapiens 135-138 9181527-4 1997 In this study, we evaluated the efficacy of ribavirin and IFN-alpha combination therapy for IFN-alpha resistant chronic hepatitis C. Twenty-four IFN-alpha non-responders and 24 relapsers were randomized to receive either ribavirin (1000 mg per day) together with IFN-alpha (3-6 million units (MU) thrice weekly) or the same dose of IFN-alpha alone, for 6 months. Ribavirin 44-53 interferon alpha 1 Homo sapiens 92-101 9186825-9 1997 The sustained response rate was significantly higher for interferon-ribavirin combination therapy than for interferon or ribavirin monotherapy (odds ratio IFN-Riba vs IFN = 9.8, 95% CI 1.9-50). Ribavirin 68-77 interferon alpha 1 Homo sapiens 155-158 9186825-9 1997 The sustained response rate was significantly higher for interferon-ribavirin combination therapy than for interferon or ribavirin monotherapy (odds ratio IFN-Riba vs IFN = 9.8, 95% CI 1.9-50). Ribavirin 68-77 interferon alpha 1 Homo sapiens 167-170 9186825-9 1997 The sustained response rate was significantly higher for interferon-ribavirin combination therapy than for interferon or ribavirin monotherapy (odds ratio IFN-Riba vs IFN = 9.8, 95% CI 1.9-50). Ribavirin 121-130 interferon alpha 1 Homo sapiens 155-158 9186825-9 1997 The sustained response rate was significantly higher for interferon-ribavirin combination therapy than for interferon or ribavirin monotherapy (odds ratio IFN-Riba vs IFN = 9.8, 95% CI 1.9-50). Ribavirin 121-130 interferon alpha 1 Homo sapiens 167-170 9186825-10 1997 The estimated probability of sustained response following interferon-ribavirin combination therapy was 51% for patients without previous IFN therapy, 52% for patients with previous IFN therapy and response-relapse, and 16% for previous IFN non-responders. Ribavirin 69-78 interferon alpha 1 Homo sapiens 137-140 9186825-10 1997 The estimated probability of sustained response following interferon-ribavirin combination therapy was 51% for patients without previous IFN therapy, 52% for patients with previous IFN therapy and response-relapse, and 16% for previous IFN non-responders. Ribavirin 69-78 interferon alpha 1 Homo sapiens 181-184 9186825-10 1997 The estimated probability of sustained response following interferon-ribavirin combination therapy was 51% for patients without previous IFN therapy, 52% for patients with previous IFN therapy and response-relapse, and 16% for previous IFN non-responders. Ribavirin 69-78 interferon alpha 1 Homo sapiens 181-184 9181527-4 1997 In this study, we evaluated the efficacy of ribavirin and IFN-alpha combination therapy for IFN-alpha resistant chronic hepatitis C. Twenty-four IFN-alpha non-responders and 24 relapsers were randomized to receive either ribavirin (1000 mg per day) together with IFN-alpha (3-6 million units (MU) thrice weekly) or the same dose of IFN-alpha alone, for 6 months. Ribavirin 44-53 interferon alpha 1 Homo sapiens 92-101 9181527-4 1997 In this study, we evaluated the efficacy of ribavirin and IFN-alpha combination therapy for IFN-alpha resistant chronic hepatitis C. Twenty-four IFN-alpha non-responders and 24 relapsers were randomized to receive either ribavirin (1000 mg per day) together with IFN-alpha (3-6 million units (MU) thrice weekly) or the same dose of IFN-alpha alone, for 6 months. Ribavirin 44-53 interferon alpha 1 Homo sapiens 92-101 9181527-4 1997 In this study, we evaluated the efficacy of ribavirin and IFN-alpha combination therapy for IFN-alpha resistant chronic hepatitis C. Twenty-four IFN-alpha non-responders and 24 relapsers were randomized to receive either ribavirin (1000 mg per day) together with IFN-alpha (3-6 million units (MU) thrice weekly) or the same dose of IFN-alpha alone, for 6 months. Ribavirin 44-53 interferon alpha 1 Homo sapiens 92-101 9011471-0 1996 Interferon-ribavirin combination therapy for chronic hepatitis C. Following preliminary reports of small studies that suggested a clinically important enhanced benefit from combination therapy with interferon-alpha (IFN) and ribavirin over IFN monotherapy in chronic hepatitis C, a meta-analysis of data from these studies was performed to estimate the efficacy and tolerability of combination therapy in chronic hepatitis C. Records were obtained from 59 patients who had received combination therapy with IFN 3 MU three times weekly and ribavirin 1000-1200 mg daily for six months and were followed for six months after stopping combination therapy. Ribavirin 11-20 interferon alpha 1 Homo sapiens 216-219 9011471-5 1996 This meta-analysis of IFN-ribavirin combination therapy for chronic hepatitis C suggests that combination therapy results in a two- to threefold greater efficacy than IFN monotherapy, whereas side effects are similar to IFN monotherapy, with the exception of ribavirin-induced anemia. Ribavirin 26-35 interferon alpha 1 Homo sapiens 22-25 7949457-13 1994 Ribavirin, which has a significant antiviral effect on hepatitis C virus, might be useful in combination with IFN-alpha. Ribavirin 0-9 interferon alpha 1 Homo sapiens 110-113 7629562-3 1995 The objective of our study is to verify whether the combination ribavirin (R)+ IFN-alpha can lead to positive results in non-responders to treatment with IFN-alpha alone. Ribavirin 64-73 interferon alpha 1 Homo sapiens 154-163 7521308-0 1994 A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. BACKGROUND/AIMS: In chronic hepatitis C, interferon alfa (IFN-alpha) therapy fails to achieve a sustained response in approximately 75% of patients. Ribavirin 42-51 interferon alpha 1 Homo sapiens 182-191 7521308-2 1994 The aim of this study was to evaluate whether ribavirin and IFN-alpha in combination could be effective in IFN-alpha-resistant chronic hepatitis C. METHODS: Twenty patients with chronic hepatitis C resistant to a previous course of IFN-alpha were randomly assigned to receive either ribavirin combined with IFN-alpha or IFN-alpha alone for 6 months. Ribavirin 46-55 interferon alpha 1 Homo sapiens 107-116 7521308-2 1994 The aim of this study was to evaluate whether ribavirin and IFN-alpha in combination could be effective in IFN-alpha-resistant chronic hepatitis C. METHODS: Twenty patients with chronic hepatitis C resistant to a previous course of IFN-alpha were randomly assigned to receive either ribavirin combined with IFN-alpha or IFN-alpha alone for 6 months. Ribavirin 46-55 interferon alpha 1 Homo sapiens 107-116 7521308-2 1994 The aim of this study was to evaluate whether ribavirin and IFN-alpha in combination could be effective in IFN-alpha-resistant chronic hepatitis C. METHODS: Twenty patients with chronic hepatitis C resistant to a previous course of IFN-alpha were randomly assigned to receive either ribavirin combined with IFN-alpha or IFN-alpha alone for 6 months. Ribavirin 46-55 interferon alpha 1 Homo sapiens 107-116 7521308-2 1994 The aim of this study was to evaluate whether ribavirin and IFN-alpha in combination could be effective in IFN-alpha-resistant chronic hepatitis C. METHODS: Twenty patients with chronic hepatitis C resistant to a previous course of IFN-alpha were randomly assigned to receive either ribavirin combined with IFN-alpha or IFN-alpha alone for 6 months. Ribavirin 46-55 interferon alpha 1 Homo sapiens 107-116 7521308-6 1994 CONCLUSIONS: These findings suggest that ribavirin plus IFN-alpha combination therapy is able to induce a sustained biochemical and virological response in a significant proportion of patients with IFN-alpha-resistant chronic hepatitis C. Ribavirin 41-50 interferon alpha 1 Homo sapiens 198-207 34960758-5 2021 We also demonstrated that IFNalpha combinations with sofosbuvir, telaprevir, NITD008, ribavirin, pimodivir, or lamivudine were effective against HCV, HEV, FLuAV, or HIV at lower concentrations, compared to monotherapies. Ribavirin 86-95 interferon alpha 1 Homo sapiens 26-34 11114411-6 2000 Proliferation was suppressed 57-99% (P<0.001) by IFN-2b (10(5)-10(7) IU/ml), 41-74% (P<0.001) by CIFN (1.5-150 ng/ml), and 10-94% (P<0.001) by RBV (0.5-50 microg/ml). Ribavirin 152-155 interferon alpha 1 Homo sapiens 52-55